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Abstract
Metabolomics lies at the fulcrum of the system biology ‘omics’. Metabolic profiling offers
researchers new insight into genetic and environmental interactions, responses to pathophysi-
ological stimuli and novel biomarker discovery. Metabolomics lacks the simplicity of a single
data capturing technique; instead, increasingly sophisticated multivariate statistical techniques
are required to tease out useful metabolic features from various complex datasets. In this work,
two major metabolomics methods are examined: Nuclear Magnetic Resonance (NMR) Spec-
troscopy and Liquid Chromatography-Mass Spectrometry (LC-MS). MetAssimulo, an 1H-NMR
metabolic-profile simulator, was developed in part by this author and is described in the Chap-
ter 2. Peak positional variation is a phenomenon occurring in NMR spectra that complicates
metabolomic analysis so Chapter 3 focuses on modelling the effect of pH on peak position.
Analysis of LC-MS data is somewhat more complex given its 2-D structure, so I review existing
pre-processing and feature detection techniques in Chapter 4 and then attempt to tackle the
issue from a Bayesian viewpoint. A Bayesian Partition Model is developed to distinguish chro-
matographic peaks representing useful features from chemical and instrumental interference
and noise. Another of the LC-MS pre-processing problems, data binning, is also explored as
part of H-MS: a pre-processing algorithm incorporating wavelet smoothing and novel Gaussian
and Exponentially Modified Gaussian peak detection. The performance of H-MS is compared
alongside two existing pre-processing packages: apLC-MS and XCMS.
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Chapter 1
Introduction
1.1 Metabolomics
In the post-genomic era there has been a massive growth in ‘omics’ techniques investigating
different levels of biological organisation. At the core of systems biology research is metabolic
profiling, commonly known as metabolomics. Metabolomics focuses on high-throughput identi-
fication and quantification of metabolites, small molecules (≤ 1500Da) involved in metabolism
[6]. When attempting to relate genes to the overall function of a system, the metabolome (the
complete set of metabolites of an organism) more closely reflects the activities of the organism
at a functional level than, for example, the transcriptome [7]. Metabolic fluxes are not only
regulated by gene expression, but also by additional factors, which include the abundance of
metabolites as substrates (molecules acted upon by enzymes) and products (the output of a re-
action or process) [8]. Therefore metabolic profiling adds another dimension to our understand-
ing of biological systems. Figure 1.1 illustrates, somewhat simplistically, how metabolomics fits
into the ‘omics’ structure of systems biology. In reality, the interactions between omics are
not one-way only and much research is devoted to understanding the complex ’inter-omics’
mechanisms in order to build up a holistic view of an organism’s function. The omics research
areas mentioned here are by no means an exhaustive list and the depth and breadth of omics
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specialities is continuously expanding.
Genomics → Transcriptomics → Proteomics → Metabolomics (1.1)
With the relatively recent development of systems biology comes the promise of ‘personalised
health-care solutions’ and an improved understanding of molecular epidemiology [9]. The ap-
plications of accurate metabolic profiling reach from studying drug toxicity and pharmacology
to disease-screening for conditions such as diabetes or cancer [10, 11, 12, 13, 14]. Metabolomics,
as an expression of genetic and environmental factors, is key to furthering our knowledge of
how humans and other organisms function as individuals and interacting complex systems.
There are generally considered around 2000 major metabolites for humans, however this number
increases significantly when secondary metabolites are explored [15, 16]. Although the terms
‘metabonomics’, ‘metabolomics’, metabolic ‘fingerprinting’ or ‘profiling’ were assigned subtly
different definitions originally, they are usually used interchangeably today. Metabolomics can
be formally defined as ‘the comprehensive quantitative analysis of all the metabolites of an
organism or specified biological sample’, typically involving ‘the quantitative measurement of
the multi-parametric time-related metabolic responses of a complex (multi-cellular) system to
a pathophysiological intervention or genetic modification’ [9].
1.2 Technologies
Metabolomics lacks a definitive data-acquisition technique, with a variety of methods offering
different advantages and disadvantages depending on the aims or priorities of a study or ex-
periment. However, the two main techniques for capturing metabolite data are 1H Nuclear
Magnetic Resonance (NMR) Spectroscopy and Mass Spectrometry (MS) [17, 18]. Metabolites
in biofluids are in dynamic equilibrium with those in cells and tissues so their metabolic profile
reflects changes in the state of an organism due to disease or environmental effects. NMR
is highly reproducible, offering the advantage of being non-destructive, and is able to give a
nearly global metabolite profile including structural information enabling the identification of
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the most abundant metabolites. MS boasts a significantly superior sensitivity [19, 17], but has
great variability of results as consequence which is exacerbated by time-consuming and error-
prone sample preparation procedures. There are efforts under way within the metabolomic
community to marry the merits of both NMR and MS and forge a multi-platform approach
to metabolomics research [20, 21, 22]. Whilst NMR spectra are typically characterised by a
1-dimensional signal whose intensity varies in proportion to metabolite concentrations detected
across a scale of ‘parts per million’ (ppm) of an internal standard, MS is usually paired with
a chromatographic technique such as liquid or gas chromatography (LC-MS or GC-MS [23])
resulting in a 2-dimensional dataset of intensities varying in both retention time (Rt) and along
the mass-to-charge ratio scale (m/z). Metabolites present as ‘peaks’ in the data, where the
instrument has registered the presence of a molecular species within the biofluid. NMR ma-
chines are typically more expensive with faster running time, but LC-MS machines certainly
have more widespread availability. Use of GC-MS has largely been superseded by LC-MS due
to more convoluted sample preparation, limitations on the size and type of molecules that can
be measured as well as slow speed of data acquisition. Despite this, GC-MS is still used in
plant metabolomics.
1.2.1 1H Nuclear Magnetic Resonance Spectroscopy
1H-NMR spectroscopy gives an almost global metabolic profile as it has the potential to detect
nearly all proton-containing metabolites and allows metabolites to be detected simultaneously
without pre-selection. Biofluids contain thousands of metabolites, but a typical NMR spec-
trum will only contain signals from a few hundred of the most abundant metabolites. Despite
relatively poor sensitivity in comparison with analytical methods such as mass spectrometry,
NMR spectroscopy requires minimal sample preparation meaning the process is highly repro-
ducible, and is able to measure concentrations as low as 100µM [24] and even lower with recent
techniques such as cryoprobe technology [25]. NMR spectroscopy utilises the fact that under
a magnetic field, the atomic nuclei (in this case, 1H) absorb at a frequency proportional to the
strength of the field, by detecting the resonance of hydrogen nuclei. When placed in a magnetic
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field, the magnetic moment of the hydrogen atom adopts one of the two permitted orientations
of different energy. The difference in energy of these two states depends on the strength of in-
teraction between the magnetic moment of the nucleus and the field [26]. This energy difference
can be measured by applying electromagnetic radiation of a certain frequency which causes the
nuclei to shift between states. ‘Chemical shift’ is defined as the effect of the chemical structure
of the molecule on the resonance frequency of the nuclei. Therefore the NMR spectrum for
each metabolite is comprised of a characteristic pattern of peaks or resonances, derived from
three main factors:
1. The chemical shift (δ) of each resonance is dependent upon the local magnetic field ex-
perienced by each nucleus. This local field is dependent on the degree to which molecular
orbitals shield the influence of the external spectrometer field. Thus the chemical shift re-
flects the chemical structure and bonding configuration of the metabolite. Whilst Hz is the
fundamental energy unit of NMR, the frequency reported is dependent on the magnetic field
strength so the position of each peak is measured relative to that of an internal standard and
given in a scale of parts per million (ppm) instead [26]. A commonly used internal standard is
3-(Trimethylsilyl)-Propionic acid-D4 (TSP).
2. Spin-spin coupling (also known as scalar coupling or J-coupling) is the phenomenon of
magnetic interactions between nearby nuclei. This means a proton has more than one resonant
frequency resulting in a juxtaposition of peaks called a ‘multiplet’ as shown in Figure 1.1, with
the pattern determined by the chemical structure of the molecule.
Figure 1.1: Example of a NMR multiplet signal resulting from spin-spin coupling.
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3. Integrated peak area for a given metabolite is proportional to the number of observed 1H
nuclei (assuming there are no differential relaxation effects) and allows quantification of the
metabolite concentrations.
The resulting dataset consists of a series of resonance intensity measurements taken over a
grid of frequencies, with the x-axis corresponding to the resonant frequency (usually plotted
to increase from right to left) and the y-axis gives the resonance intensity (see Figure 1.2).
The spectrum of a pure compound will consist of a ‘signature’ of peaks reflecting the factors
described. Under ideal conditions, each peak takes the form of a Lorentzian curve, represented
by the following equation:
lγ(x) =
2γ
pi(4x2 + γ2)
(1.2)
where γ is referred to as the ‘linewidth’ (or ‘peak-width at half-height’). The NMR spectrum
Figure 1.2: A typical 1H NMR spectrum of a human urine sample with some labelled metabolite
resonances, where the x-axis is ppm (parts per million) relative to some internal standard and
the y-axis gives the signal intensity.
of a complex mixture can be well approximated by a linear combination of the spectra of
pure compounds, i.e a biofluid spectra containing K different metabolites can be treated as
K-dimensional objects, in which each dimension represents the concentration signal of a single
metabolite [27]. This superposition of peaks and multiplets results in a complex spectrum of
overlapping signature patterns. These spectra can be further complicated by peak positional
variation, due to matrix effects or differences in experimental conditions as well as variation in
the chemical properties of the sample, e.g pH value and the strength of other ionic species in the
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mixture [28]. These problems, along with background noise and the presence of contaminants,
make peak identification very difficult particularly for automated algorithms.
Pre-processing is typically performed to provide a dataset that is more informative for sta-
tistical modelling. The data is usually transformed into a matrix of m variables (metabolite
concentrations or metabolic signals) by n samples. This may be achieved by first identifying in-
dividual metabolite signals and quantifying them (both non-trivial tasks), or by ‘binning’ (also
referred to as ‘bucketing’) the spectra into equal regions (typically 0.04ppm wide). Binning
is often preferred to using the entire chemical shift resolution as not only does it reduce the
dimension of the data, but may also limit the effect of peak positional variation. Alternatively,
variation in peak position can be reduced by using an alignment procedure [29]. Normalisation
of the matrix rows may be performed with the aim of removing variation between samples by
multiplying by a constant. The samples may be normalised relative to an internal standard
or the total integrated intensity across the spectrum, depending on whether it is more impor-
tant to determine absolute or relative levels of metabolite concentrations. Another option is to
normalise the spectra with respect to a selected ‘reference’ spectra using probabilistic quotient
normalisation or histogram normalisation for example, but knowledge of the biological context
of the data is essential when choosing a normalisation method [30, 29]. Sometimes the columns
of the data matrix will also be scaled, allowing more emphasis to be placed on low intensity
signals. Variables are often scaled to unit variance, or alternatively Pareto or Log scaling may
be used [25]. Another typical pre-processing step is to remove the spectral region worst affected
by the unwanted water signal, since suppression of these large resonances is usually imperfect.
The next step in the statistical analysis of metabolic NMR data is to perform both unsupervised
(exploratory) and supervised (e.g. classification/regression) analysis, with the aim of identifying
and characterising important differences between classes resulting from the presence of external
or internal stimuli to the organism. Classical methods (employed in metabolomic analysis across
technologies) include Principle Components Analysis (PCA) and Partial Least Squares (PLS)
regression, which aid interpretation of the data by projecting onto lower dimension spaces
corresponding to either the highest variance, or highest covariance between the scores of the
data and the response variable. Typically the analysis workflow will include firstly unsupervised
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clustering such as PCA and then be followed by a supervised method (PLS-DA etc.) to enhance
this separation and understand which variables are responsible for the differences between
datasets.
PCA is a useful exploratory analysis tool. PCA transforms a dataset consisting of observations
of several variables into a set of orthogonal ’principal components’. The principal components
are ordered in such a way that the first accounts for the as much variance in the data set
as possible and the last accounts for the least, whilst maintaining orthogonality between the
components. PCA scores correspond to a linear combination of the original variables and can be
defined as the transformed variable values corresponding to a particular data point. Loadings
describe the weight that each original variable contributes to the component score. Usually,
the dimensionality of the problem is reduced by considering only the first two or three principal
components as they will typically account for most of the variability of the data. This technique
is particularly relevant for metabolomics given the original variables are highly collinear.
PLS is a broad class of techniques for modelling relations between variable sets using latent vari-
ables. Generally speaking PLS creates orthogonal score vectors (or components) that maximise
covariance between different sets of variables by projecting both the predictors and outcomes
to a new space. It is particularly useful when the variables outnumber the observations and are
highly collinear. Whilst PCA chooses the x-axis scores to explain as much factor variation as
possible, PLS chooses x and y scores so that the relationship between successive pairs of scores
is as strong as possible as expressed by covariance of scores. As such, PLS scores reflect the
covariance structure between predictors and response, with the aim being to maximise covari-
ance between the response variable and component scores. Extensions of these methods, for
example PLS regression, Orthogonal (O/O2-PLS) PLS and Discriminant Analysis (PLS-DA),
are also used throughout the metabolomic community. Alternative approaches include Sup-
port Vector Machines, Genetic Algorithms and Programming, kernel methods and tree-based
classifiers (e.g. Random Forests) [30, 25].
Statistical Spectroscopy is a collection of tools that has been rapidly expanding since the de-
velopment of Statistical Total Correlation Spectroscopy (STOCSY) [31]. STOCSY utilizes
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correlation analysis to construct a pseudo-2D spectrum providing useful information on cor-
related metabolic signals in 1H NMR. This is useful for identifying signals belonging to the
same compound (some molecules have more than one signal for each measurement) as well as
highlighting correlated metabolites which may be part of the same metabolic pathway. The
methods used by STOCSY have now been extended to tackle analysis across other technologies,
for example Statistical Hetero-Spectroscopy (SHY) aims to incorporate information obtained
using MS data [32]. 2D-NMR methods employing an additional NMR nuclei, e.g. 13C, are
often used similarly in metabolomic analysis with the advantage of providing further informa-
tion useful in elucidating the chemical structure and identifying unknown molecules, as well as
signal dispersion in the additional dimension [33].
Identification of metabolite signals present in NMR data is greatly aided by the development
of several databases dedicated to documenting metabolite data. Two of the largest are the
Biological Magnetic Resonance Bank (BMRB) [34] and the Human Metabolome Database
(HMDB) [35]. Although the BMRB includes information on molecules including peptides,
proteins, and nucleic acids, the HMDB focusses specifically on small molecule metabolites found
in the human body. Whilst these databases are valuable tools, there exist several challenges
in curating the ‘ideal’ data resources. Two major problems are the unknown abundance of
unknown metabolites within the human metabolome meaning the databases are inherently
limited in their coverage, and also the relevance of acquisition conditions, for example there
may be much variation in pH, use of solvents etc for different metabolite data. In addition to the
metabolite databases for particular technologies there are useful resources linking metabolites
to particular pathways, for example Kyoto Encyclopedia of Genes and Genomes (KEGG) [36],
MetaCyc [37] and ConsensusPathDB [38].
The methods for processing and interpreting metabolic 1H NMR data are many and varied.
In Chapter 2, a package for simulating human urine 1H NMR metabolic profiles is introduced,
whilst Chapter 3 tackles the problem of modelling pH-induced peak positional variation.
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1.2.2 Liquid Chromatography - Mass Spectrometry
Most biologically interesting chemicals are present as isomers: molecules having exactly the
same mass but a different structure. Using a separation technique, such as chromatography,
before using mass spectrometry can help tackle this problem by further dispersing the signal
in an additional dimension. Another advantage of separation is that it limits the amount of
analytes being ionized simultaneously and thus reduces the possibility of ion suppression effects.
Ion suppression can also be a result of the sample matrix used and is unpredictable, impairing
detection capability, quantification and reproducibility [39, 40]. After elution, the mobile phase
Figure 1.3: A high level view of the LC-MS workflow taken from [1]. The sample enters the
liquid chromatography where compounds are separated in the time domain, then the sample is
ionized and passed to the mass spectrometer where compounds are further separated by their
mass. This results in a 2-dimensional dataset where signals are described by a (retention time
(Rt), mass-to-charge ratio, intensity) triplet.
passes through an interface before moving to the mass spectrometer. This interface either
attempts to remove the mobile phase, or pumps the solution straight into the mass spectrometer
in order to minimize contamination. Figure 1.3 illustrates the LC-MS work-flow.
Liquid Chromatography works by pumping a ‘mobile phase’ solution through the ‘stationary
phase’ or ‘column’, where the time taken from injection to elution at the detector is dependent
on the interaction between the analyte and the mobile and stationary phases. The mobile
phase is a solution containing the sample and any solvents or buffers used. Solvents are used in
order to control the strength of interaction different molecules have with the chromatographic
column, whilst buffers manage the degree of ionization of the analyte. Even high-purity solvents
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and buffers can contribute contaminant signals to background noise. The mobile phase is then
delivered into the column under high pressure in order to sustain a constant flow rate and
thus ensure reproducibility. Separation occurs when elements of the sample mixture interact to
different extents with either or both of the mobile and stationary phases and so take different
amounts of time to traverse the column. There are many different configurations of column and
mobile phases that give widely varying results depending on the physiochemical properties of
the molecules analysed [41]. Gradient elution, for example, actually varies the composition of
the mobile phase during the experiment in an attempt to achieve higher resolution separation.
LC technology is fast evolving and advances in methodology means that the peak capacity
of a single scan is ever-increasing. HPLC (High Performance Liquid Chromatography) has
been a widely used technique since the 1990s. HPLC utilises the fact that employing smaller
particles for the stationary phase of the column and injecting the mobile phase at high pressure
increases both the speed of elution and the number of peaks resolved per unit time in gradient
separations, resulting in both improved sensitivity and resolution. More recently UPLC (Ultra
Performance Liquid Chromatography, pioneered by Waters MS Technologies, Ltd., Manchester,
U.K.) has become the fore-running technique using yet smaller particles to improve performance
even further. The enhanced resolution and sensitivity means that run times are quicker and
reproducibility is better than for normal HPLC.
Mass spectrometers differentiate compounds within a complex mixture by measuring their
molecular mass-to-charge ratio. Upon entering the mass spectrometer, the sample is ionized
using one of a variety of techniques : electron or chemical ionization, fast-atom bombard-
ment (FAB), thermospray (TSP), electrospray (ESI) etc, with ESI the most commonly used in
metabolomics. ESI is a relatively ‘soft’ ionization technique that causes minimal fragmentation
and can be run in positve and negative modes in order to capture both sets of analytes. Then,
ions of different mass-to-charge ratios (m/z) are separated and the counts of each group of ions
is measured. There are several different methods for mass analysis, for instance Quadrupole
Mass Analysers vary the voltage between two pairs of rods in order to bring ions of different
m/z to the detector as required. This instrument has high sensitivity for targeted analysis
[42]. Another type of mass analyser common within metabolomics is Fourier Transform Ion
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Cyclotron Resonance (FT-ICR), which determines the m/z value based on the cyclotron fre-
quency (dependent on mass) of the ions trapped in a fixed magnetic field. The signal is Fourier
Transformed to the frequency domain in order to calculate the mass spectrum [43]. FT-ICR
has a very high mass accuracy so is particularly useful for identifying unknown analytes. Per-
haps the simplest mass separation device is the Time-Of-Flight (TOF) analyser. The ions are
first accelerated by an electromagnetic field. TOF then utilizes the fact that regardless of the
ionization technique, all the ions are given the same kinetic energy meaning that the velocity
of each is inversely proportional to the square root of its mass. Thus, the m/z of the ion can be
deduced according to how long the ion takes to traverse the flight tube of the instrument [42].
Due to its simplicity and fast scanning capability, TOF is being used increasingly in LC-MS
instrumentation to produce high-resolution spectra for untargeted applications.
Mass analysers can also be run in tandem with an alternative mass analyser (or indeed more
than one), for example QTOF mass analysers combine the strengths of Quadropole mass anal-
ysis with those of Time-Of-Flight analysis simultaneously to improve sensitivity and accuracy.
These tandem mass spectrometers can also be used to produce additional structure information
about compounds by fragmenting ions and identifying the fragments. The Quadropole analyser
may be used to select a mass range which is then measured by the TOF, or alternatively for
fragmenting ions which are then detected in the TOF analyser.
The whole process results in a 2-dimensional data set: an intensity for each retention time (Rt)
and mass-to-charge ratio (m/z) pair, as shown in Figure 1.4 [42, 44]. Metabolite quantification
relies on the fact that peak intensity (or peak volume) is usually proportional to the concen-
tration of a molecule [45]. A ‘mass spectrum’ is defined as the ions detected for one particular
retention time value, i.e. a slice in the retention time dimension, whilst slicing at constant
m/z gives a ‘chromatogram’ (Extracted Ion Chromatogram or EIC) for each m/z value. In
constructing chromatograms, one can either use the maximum intensity (resulting in a ‘Base
Peak Chromatogram’) or the total intensity at each Rt point in the slice (EIC). However, com-
plications arise in defining a m/z ‘bin’ for each chromatogram since there can be drift in the
measurement of m/z (see Figure 1.5) and this problem will be examined more closely in Chapter
4. The characteristics of peaks in the m/z direction or ‘MS peaks’ are largely determined by the
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Figure 1.4: A 2-D Intensity map of LC-MS Data from [2]. x and y axes give the Retention
Time (Rt) and mass-to-charge ratio (m/z) and z axis gives the intensity (ion count) detected.
Figure 1.5: A chromatographic peak split across three bins due to drift in m/z.
instrument used. Gaussian curves are commonly used for MS peak modelling, although other
shapes may perform better [23]. The LC peak shape is dependent on a complex interaction of
factors, not entirely understood, such as solvent concentration, separation gradient etc. Again,
many use a Gaussian curve for simplicity [46, 47], but it is acknowledged that peaks usually
have a long tail and are sometimes even bi-modal [41, 48]. Chromatographic peaks often re-
quire alignment between successive samples due to the difficulty ensuring the reproducibility
of the process resulting in non-linear distortions of the Rt axis. The chromatographic domain
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is usually used in order to discriminate between analyte and noise peaks [45].
The signal is complicated further by isotope patterns (often predictable if the compound iden-
tity is known) due to the abundance of naturally occurring isotopes, such as C13. This means
multiple peaks may be registered for a single molecular species in mass spectra at different m/z
locations. Figure 1.6 shows an example of protein MS. The mono-isotopic peak registers at
(54.7s, 526.6m/z), and at least two well-defined smaller isotopic peaks are present at 527.5m/z
and 528.3m/z. In addition to this, heavy molecules such as proteins may generate a group
of related peaks with different charge states[41]. However, metabolites are relatively small by
comparison (<1500Da) producing few, if any multiply charged ions so this is not generally a
big problem within metabolomics [42]. Other complications include fragmentation of molecules
Figure 1.6: An isotopic cluster (proteomic data acquired on a low-resolution spectrometer) as
it is visualized in a 2-D map from [3]. The x-axis and y-axis of this noise-filtered 2-D map
represent the chromatography and MS dimensions, respectively. Relevant mass spectrum and
mass chromatogram are represented as cross-sections. A contour plot of the 2-D map is shown
in the inset.
during the ionisation process, resulting in a parent and correlated daughter ions being detected.
Linking fragments (co-eluting peaks) using statistical post-processing techniques can be helpful
in identifying unknown molecules. Sometimes dimerization can occur, where two molecules of
the same species combine and so are detected as a single ion at twice the m/z value. Ionization
can also result in adducts, for example protonated or deprotonated alkali metals binding to-
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gether as well as neutral losses (water CO2 etc.) for metabolites. The mechanism behind this
process is not fully understood but given the small size of metabolites adduct formation can
significantly alter m/z values [49].
There exist numerous obstacles to overcome when interpreting LC-MS data. Tailing peaks can
often be mistaken for multiple consecutive peaks, and quantification for one peak can contain
contaminating information from a confounding overlap of signals [50]. This can be overcome
somewhat by modelling the spectra as a sum of peaks, each represented in some parametric
form and then performing deconvolution, but this can introduce new errors. The signal can be
corrupted by ionization and ion-suppression effects, usually arising when polar contaminants
are competing with the target analyte present for available ions, as well as by impurities from
the buffers and solvents used [17].
Noise is usually characterized by high frequency, low intensity, narrow peaks, and is generally
more prevalent at the beginning and end of elution. Most molecules elute with an intensity
markedly greater than the expected level of noise, but molecules eluting with a low abundance
makes them extremely difficult to identify. Feature detection is hampered further by non-linear
drifts in retention time (and sometimes m/z values as mentioned earlier). In addition, aligning
spectra across many samples is complicated by peaks that are missing or simply undetected in
some samples, providing another huge challenge beyond the scope of this thesis [45].
Similarly to NMR there exist reference databases for MS spectra, such as MassBank [51] and
METLIN [52]. However, since the between-sample variation of elution times for even the same
instrument can be so large, no Rt index is currently available for LC-MS [53]. In adition to spec-
tral library matching, a combination of techniques, such as NMR, are usually required to gain
enough structural information to confirm a metabolite identity. Sample preparation method,
choice and configuration of LC-MS instrumentats and algorithm/software employed for data
processing can result in widely varying datasets even from the same sample. Pharmaceutical
regulators are moving to introduce standard protocols in an effort to make results more stan-
dardised and comparable (Metabolomics Standard Initiative) and use of pilot studies, internal
standards, QCs and other ’quality assurance’ measures are widely used in order to tackle the
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issue of reproducibility and robustness of results.
1.3 Bayesian Inference
Both NMR and LC-MS require sophisticated statistical techniques in order to perform inference
on the data obtained. Within statistics there are two main inferential frameworks: ‘frequentist’
and ‘Bayesian’. Frequentist inference is based upon the assumption that the observed data can
be considered as one instance of a series of infinitely repeatable experiments [54] and standard
frequentist methodologies include statistical hypothesis testing and calculating confidence in-
tervals. Whilst frequentists tend to consider the probability of the observed data arising given
a hypothesis, Bayesians are more converned with the probability of a hypothesis given the
observed data. Bayesian inference is derived from Bayes’ Theorem (Equation 1.3):
p(θ|y, φ) = p(y|θ)p(θ|φ)
p(y|φ) (1.3)
where p(y|θ) is the likelihood of the data given the model parameters, θ is a parameter of the
likelihood distribution with prior θ ∼ p(θ|φ), φ is a hyper-parameter of the distribution of θ,
p(y|φ) is the marginal likelihood:
p(y|φ) =
∫
θ
p(y|θ)p(θ|φ)dθ (1.4)
and p(θ|y, φ) is the posterior probability of parameter θ.
Practically speaking this means setting up a full probability model, conditioning on the ob-
served data (y) in order to calculate the posterior distribution (the conditional probability
distribution of the unobserved quantities of interest, given the observed data) and then evalu-
ating the model fit [55]. Frequentist ‘results’ are usually true or false conclusions drawn from
significance tests, whereas Bayesian results more often take the form of probability distributions
for parameters that attempt to describe the data. Bayesian methodology is employed widely
within metabolomics for a variety of different purposes, for example variable selection/dimen-
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sion reduction, latent variables analysis, network/pathway analysis and spectral deconvolution
among many others.
When practicing Bayesian inference, it is often useful to be able to calculate posterior estimates
of characteristics of the model parameters. In the case of multi-parameter models, where θ =
(θ1, ..., θk), this requires averaging over ‘nuisance’ parameters (parameters on which one is not
concerned with performing inference). Supposing the parameter of interest is θ1, the conditional
distribution p(θ1|y) must be derived from the joint posterior distribution p(θ|y) = p(θ1, ..., θk|y).
Averaging over the nuisance parameters gives:
p(θ1|y) =
∫
θk
...
∫
θ2
p(θ1, ..., θk|y)dθ2...dθk (1.5)
or alternatively
p(θ1|y) =
∫
θk
...
∫
θ2
p(θ1|y, θ2, ..., θk)p(θ2, ..., θk|y)dθ2...dθk (1.6)
However, these posterior distributions are often high dimensional and very difficult to calculate
either analytically or numerically. The problem of making inferences on this type of distribution
is addressed by using Markov Chain Monte Carlo (MCMC) methods. MCMC enables simula-
tion of random draws from a complex probability distribution, say f(x). MCMC methods are
based on Markov Chains, which are stochastic processes Xt, t = 0, 1, 2, ... such that:
P (Xn = xn|X0 = x0, ..., Xn−1 = xn−1) = P (Xn = xn|Xn−1 = xn−1) (1.7)
i.e. the current observation only depends on the previous one and not the entire observation
history [54]. MCMC methods essentially involve constructing a Markov Chain whose target
distribution is the distribution of interest f(x). Once a large enough sample has been simulated,
the functionals of interest can be calculated to any degree of accuracy.
There are numerous methods for building the required Markov Chain. For example Metropolis-
Hastings uses a ‘proposal distribution’ q(x) to propose a candidate value Y for Xt+1, possibly
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depending on Xt, and accepts it with probability α(Xt, Y ) where
α(Xt, Y ) = min(1,
f(Y )q(Xt|Y )
f(Xt)q(Y |Xt)) (1.8)
and f(x) is the function of interest. A special case of the Metropolis-Hastings is the Gibbs
sampler. Suppose draws of θ = (θ1, ..., θk) must be obtained from the joint distribution function
f(θ1, ...θk). Then for each draw t = 1, 2, ..., each θ
(t)
i is sampled from the conditional distribution
given by p(θ
(t)
i |θ(t)1 , ..., θ(t)i−1, θ(t−1)i+1 , ..., θ(t−1)k ) (proportional to the joint distribution) so that each
variable is sampled using the most recently updated values of the other variables. There are
many variations on these samplers, so-called ‘adaptive’ modifications aimed to increase the
sampling efficiency of the algorithms.
A ‘burn-in’ period is usually utilised (i.e. the first M iterations are discarded) as we accept we
are unlikely to choose good starting conditions and thus the initial estimates are likely to be
poor. Thinning is the practice of saving only every n-th iteration sometimes with the aim of
speeding up post-processing or reducing required memory but also as an attempt to remove
auto-correlation. For example, to obtain a run of 10,000 iterations one would run n × 10, 000
simulations and save only every n-th one. However it has been argued that if the entire chain
is long enough, the auto-correlation has likely averaged out anyway and thinning provides little
additional benefit to this end [56].
Convergence of MCMC is a major concern for Bayesian statisticians with the parameters es-
timated often correlated with themselves over the iterations or with each other making con-
vergence slow and difficult to execute. Despite much theoretical research into convergence
computations, there is limited benefit thus far for practical applications. Although it remains
impossible to be certain that your MCMC sample is truly representative of the target distri-
bution, there are many diagnostic measures and techniques to help somewhat evaluate success.
Indeed Cowles and Carlin provide thorough reviews of these[57].
One of the simplest checks is visualisation of how well your chains are ‘mixing’ or moving
around the sample space. Plotting traces (parameter value vs. iteration number) can show
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you if your parameter gets stuck or moves poorly. ‘Running mean plots’ (plotting the sample
mean up to each iteration vs. iteration number) can also be useful to this end. Investigating
the auto-correlation can also provide clues as to the convergence of your chain. A ‘k-th lag
auto-correlation’ can be computed and we would expect the correlation to decrease as the lag
increases. Persistently high auto-correlation for high k is again indicative of poor mixing.
One commonly used convergence diagnostic is the ‘Gelman and Rubin Multiple Sequence Di-
agnostic’ which is calculated using multiple chains per parameter. Consider the ‘potential scale
reduction factor’:
Rˆ =
√
ˆV ar(θ)
W
(1.9)
where ˆV ar(θ) is the estimated variance of the target distribution as a weighted average of the
within-chain, W , and between-chain, B, variances:
ˆV ar(θ) = (1− 1
n
)W +
1
n
B (1.10)
When Rˆ is high (> 1.1 or so) this indicates the chains should be run longer to improve con-
vergence. A ‘Gelman plot’ shows how the potential scale reduction factor changes through the
iterations and is another useful diagnostic.
There are several software packages available for automating the Bayesian analysis of models
via MCMC methods. WinBUGS (arising from the BUGS - ‘Bayesian inference Using Gibbs
Sampling’ project based in the MRC Biostatistics Unit at Cambridge, England) is one of the
most popular [58]. It provides a framework for defining Bayesian hierarchical models and a
library of sampling routines to perform inference. Several extensions have been developed
allowing construction and analysis of ever more complicated models. One such alternative,
JAGS (Just Another Gibbs Sampler), was developed with the objective of being an open-source
engine for the BUGS language [59]. JAGS is highly extensible and allows users to develop new
libraries and add-ons. Both WinBUGS and JAGS can interface to R, making them useful tools
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in the arsenal of any Bayesian statistician. Whilst MATLAB was used extensively during the
development of this thesis to write new algorithms, both WinBUGS and JAGS were used (via
R) to perform Bayesian statistical analyses.
Bayesian methods are used throughout ‘omics’ analysis from processing and analysing NMR
[60], LC-MS [61, 62] and GC-MS [63] data among others, to elucidating metabolic pathways
[64]. Within metabolomics, particularly when modelling data that is driven by some complex
physio-chemical reaction, the Bayesian framework allows us to incorporate prior knowledge of
this underlying mechanism whilst allowing the observed data to speak to us about the other
unknown interactions occurring that result in both structured and unstructured variability.
1.4 Aims
The major bottlenecks within metabolomics research can be broadly categorised as metabolite
identification, data processing and interpretation of results. Metabolite identification depends
on the robustness of the data capture, ability to match with standards and is complicated by
the great variability of molecular structures and abundance. Data processing and reduction
techniques are complex and often bespoke depending on the focus area of a given laboratory,
meaning that different results can be produced from a single dataset by using alternative
software or statistical methods hampering reproducibility and validation by different research
groups. In addition to this, manufacturers’ processing software is often tied to their particular
spectrometer, although open source software developers and researchers attempt to produce
algorithms that perform competitively whilst being compatible with multiple machine types
used across different labs. Further downstream in the data flow, all these issues greatly affect
the ability to assign biological significance to experimental results, i.e. the ultimate aim of most
metabolomic investigations. Given the complex nature of the numerous statistical challenges
facing metabolomics research, this thesis sets out to tackle a few of these problems.
• In order to fulfil the need within metabolomics for simulated 1H-NMR data with which
to develop and test new techniques for statistical inference, Chapter 2 presents a novel
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package ‘MetAssimulo’, designed to draw on data from the Human Metabolome Database
(HMDB) and an NMR Standard Spectra Database (NSSD) in order to simulate realistic
human urine spectra [65]. It also allows inclusion of peak shift and inter-metabolite
correlations.
• Chapter 3 aims to further demystify 1H-NMR metabolic profile data by Bayesian mod-
elling of the relationship between pH and peak positional variation. Being able to estimate
peak shift parameters would be of great use in the deconvolution of NMR spectra and
also accurately simulating peak shift using MetAssimulo.
• In Chapter 4 I move on to the challenges faced in the processing of LC-MS data, taking a
look at existing algorithms and the variety of techniques used. A Bayesian Change Point
Model is also explored for this application. H-MS, a novel method for data-binning and
peak detection, is described and its performance is compared to an adaptive technique
apLC-MS [66] and a commonly used package XCMS [46].
Chapter 2
Simulation of Realistic 1H-NMR
Metabolic Profiles: MetAssimulo
Metabolic NMR spectra are highly complex and the field benefits greatly from the application
of machine learning and other statistical tools to extract information. Pattern recognition
analyses such as Principal Components Analysis (PCA) have long been combined with NMR to
investigate normal and pathological metabolic states [67]. Data processing methods are being
developed to extract metabolite information and concentrations from raw spectra, allowing
automation of spectral processing. Development of advanced mathematical, statistical and
computational methods are also essential for characterisation of the metabolic state, delineation
of metabolic changes over time and the efficient identification of potential biomarkers. There
are a wide variety of diseases where key changes in metabolites have been deduced e.g. cancer,
diabetes, hypertension etc. [68, 69, 14]. However, as algorithms and methods are developed,
they need to be refined and validated to ensure results will be biologically meaningful. It is
hard to effect this without using test datasets where the true answers are known; this can
be accomplished using simulation techniques. An alternative approach is to design artificial
mixtures of metabolites which are prepared and analysed in identical fashion to real samples.
However this is expensive in terms of man power and instrument time, and offers few advantages
over in silico simulation when assessment of analytical procedures is not required.
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The purpose of MetAssimulo is to simulate datasets of realistic NMR spectra with known
parameters in order to test data analysis techniques, hypotheses and experimental designs.
Few methods for generating simulated NMR datasets have appeared in the literature to date
[70, 71]. Most model a limited number of metabolites, make no attempt to reproduce real-
istic levels of metabolites, and do not allow for between-metabolite or ‘inter-metabolite’ cor-
relations ([71] excepted) and do not always model peak positional shifts. It is common to
fit Lorentzian peak shapes in an attempt to characterize spectral peaks, e.g [70]. However,
this ignores the fact that peak shapes in real NMR profiles are variable and can be far from
ideal. Here a novel approach is outlined: making use of individual standard metabolite data
extracted from the Human Metabolome Database (HMDB) [35] and a local NMR standard
spectra database (NSSD). Many metabolic profiling labs host their own NSSD appropriate
to the biological systems and sample types they work with and thus the simulations can be
tailored to virtually any sample type or organism as required. In this work human urine is
used as the example biofluid as it is one of the most widely used in the field and, in healthy
subjects, has no protein or lipid content, both of which make the simulation more complex.
MetAssimulo is written in MATLAB with a graphical interface allowing the user to alter pro-
cessing parameters and add new standard spectra as needed. The software is freely available
along with an example NSSD of 48 metabolites commonly found in normal human urine (at
http://cisbic.bioinformatics.ic.ac.uk/metassimulo/). It must be stressed that this list
of metabolites and their concentration means and standard deviations does not constitute a
definitive description of human urine; such a goal is beyond the scope of this chapter. It is
provided for the sole purpose of demonstrating the capabilities of the software.
MetAssimulo was initially developed by a student Rebecca Jones. Rebecca worked on the first
version of MetAssimulo able to simulate peak shifts. The author’s work built on this: bug fixes,
incorporating metabolite correlations, extracting data from the HMDB and increasing efficiency
which required a substantial amount of recoding. This chapter is based on the MetAssimulo
article published in BMC Bioinformatics [65].
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2.1 Implementation
MetAssimulo performs various functions accessed though the Graphical User Interface (GUI):
pre-processing the pure spectra, simulating metabolite concentrations, incorporating peak shifts
and creating the final mixture spectrum, shown in Figure 2.1. By default it produces two groups
of spectra based on different metabolite mixtures; these could represent controls (normal) and
cases (diseased) subjects. Each metabolite has a characteristic pattern of peaks on a linear
Figure 2.1: A high level flow chart of the MetAssimulo algorithm.
scale, the chemical shift, given by δ in ppm. The signal intensity, y(δ), in a spectrum of
metabolites k = 1, .., K (where K is the total number of metabolites in the mixture) at a given
δ increases proportionally to the concentration of each metabolite, ck, present in the sample and
their number of observed protons, pk. The different metabolite spectra are summed together to
produce the overall mixture spectrum. Normally distributed additive noise (δ) ∼ N(0, σ2) (see
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‘Calculate noise standard deviation’ section for estimate of σ2) is then added to the mixture
spectrum y(δ), as in Equation 2.1:
y(δ) =
K∑
k=1
(yk(δ)ckpk) + (δ) (2.1)
This is is then smoothed to simulate the conventional preprocessing technique of exponential
apodization prior to Fourier Transform [72]. Each individual metabolite spectrum is sampled
at a series of n uniformly spaced data points. The overall spectrum is made up of pairs of
data points, (x, y) = (xi, yi)i=1,...,n, where yi = y(xi); n is set by the user, and xi defines points
sampled from the chemical shift δ.
In real NMR spectra, the signal intensity is affected by the extent to which the observed nuclei
are allowed to relax before each observation. In MetAssimulo I do not currently attempt to
simulate the effects of differential inter-molecular relaxation. However, intra-molecular relax-
ation effects are accounted for by the fact that experimentally obtained pure compound spectra
are used to form the mixture spectra.
2.1.1 Setting Parameters
Parameters can be altered either in the MetAssimulo GUI or within the parameter file ‘pa-
rameters.txt’. The interface provides the user with several different processing options. For
example the second group may be specified as fold change ratios of the concentrations of the
first group and the user can specify whether to produce output with or without peak shifts or
both. The user also chooses whether to include inter-metabolite correlation (pairwise correla-
tions between metabolites) or not; either as a textfile whose entries can be altered using the
interface or constructed from scratch in the Correlation GUI.
Input Files
The Human Metabolome Database (HMDB) [35] contains information about more than 2180
metabolites found in humans and includes literature data relating to normal and abnormal con-
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centrations in biofluids. ‘Metabocards’ is the flat file download of the entire database, available
at www.hmdb.ca. Also required is the HMDB set of NMR Peak Lists (containing locations of
individual peaks for metabolites) which is available in a downloadable zip-file. In constructing
the template of normal human urine concentrations various problems of incompleteness and/or
ambiguity were encountered. For example, in many HMDB entries the metabolite concentra-
tion mean and standard deviation is unavailable, or simply a range is given. In these cases the
standard deviation was estimated by dividing the mean (or ‘half-range’) by 1.95. There are
instances where a metabolite is identified as present in urine, but a normal concentration value
is not available. As many of these discrepancies as possible have been manually rectified in the
provided concentration file by cross-checking with other sources, i.e. literature articles, but do
not claim the result represents a complete description of human urine; it does, however serve
to demonstrate the software.
The quality of MetAssimulo simulations is also dependent on the quality and coverage of the
NSSD used, as well as the peak shift settings affecting multiplet detection. By distributing
an NSSD it is not our intention to provide a comprehensive NMR standard database but
merely an initial set of common metabolite spectra with which users can begin to make their
own simulations. Many users will wish to add their own locally acquired standard spectra for
metabolites specific to their areas of interest and I have provided functionality to do this. There
are a number of input files that are required for MetAssimulo.
• Concentration files∗ are needed for both groups of metabolites, these detail the mean
and standard deviation of the concentration for each metabolite.
• An NMR Standard Spectral Database (NSSD) comprising standard 1D 1 H-NMR
spectra for metabolites is essential. MetAssimulo is designed to work with any metabolite
database set out in the Bruker file format. Standard spectra of 48 of the most abundant
metabolites in normal human urine is distributed with MetAssimulo.
• Experiment file identifying the experiments to use in the metabolite database, as one
metabolite may have many spectra, taken at different pH for example.
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• Proton file listing the number of protons, pk observed for each metabolite, k.
• Multiplet data files∗ specifying the position of each peak in a multiplet for each metabo-
lite in order to incorporate simulated peak shifts. Known pKa values and acid/base limits
can also be included.
• Inter-metabolite correlations can be input via a text file or the GUI.
• Synonym files∗ that allow MetAssimulo to match metabolites in the HMDB data to
those in the NSSD.
• Parameter file containing the default values or simulation parameters (alterable in the
GUI).
∗ Denotes files which can be generated automatically using ‘Format HMDB Data’ function
within MetAssimulo.
Examples of all input files in the appropriate format are included with the MetAssimulo distri-
bution. Much of the required input data can be generated using the in-built function ‘Format
HMDB Data’ (accessed via the GUI) which should be run as an initial ‘setup’. It produces the
files necessary for conversion between the local database and HMDB synonyms, data required
for peak shift simulation and a raw template of concentration data for‘normal’ urine. The nor-
mal urine concentration file provided with the distribution has been hand curated to provide
realistic values and correct a number of errors found in the current version of the HMDB whilst
reducing the number of metabolites used in order to decrease processing time.
2.1.2 Pre-processing
Initially, a set of metabolite concentrations is simulated for the case and control groups, based on
the mean and standard deviations in the concentration file. Next, the required spectra from the
NSSD must be loaded. Even 1H-NMR spectra of standard pure compounds contain a number
of complexities, such as chemical and electronic noise, phase and baseline errors, contaminants
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and water suppression residuals. Thus it is ususally necessary to preprocess these spectra into
a form suitable for combining into the final metabolic profiles.
Simulating Concentrations
Concentrations, ck, for each metabolite, k = 1, .., K, are simulated for the number of replicates
specified by the user. Individual metabolite concentrations are generated from a truncated
normal distribution, Equation 2.2, using the inverse cdf method since negative concentrations
are unphysical [73]:
ck ∼ N(µk, σ2k)I(ck > 0) (2.2)
where µk is the mean concentration and σk is the standard deviation input by the user for
metabolite k.
Significant inter-metabolite correlations, here assumed to be linear pairwise correlations be-
tween metabolites, are often found within the field of metabolic profiling so they were considered
an important feature to incorporate into the simulation. Where inter-metabolite correlations
are required, the concentrations are simulated by sampling from the appropriate multivariate
normal distribution. Using the method detailed in [74] the nearest positive semidefinite corre-
lation matrix is calculated given user-specified pairwise correlations. The covariance matrix is
constructed using the metabolite standard deviations and specified correlations, and the diag-
onal entries are increased sufficiently to ensure positive-definiteness. Any necessary alterations
to the correlation and covariance matrices are output for inspection.
Read in spectrum
After the concentrations have been simulated the standard spectra of the metabolites are read
in. Each spectrum consists of chemical shift in ppm, x and intensity, y. Spectra are then
linearly interpolated onto a ppm grid of user-specified resolution.
Exclusion regions
Exclusion regions, corresponding to the location of the internal standard peak (default <
0.2ppm [75]) and the residual water peak (default 4.5ppm - 6.0ppm [75]), are set to zero. In
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urine, the urea signal (between 5.4ppm and 6.0ppm [75]), the most abundant proton-containing
metabolite [27], can be problematic particularly when water-suppression methods are used.
Water-suppression is usually imperfect and the resulting residual peaks (near to the urea sig-
nal) are not dealt with easily by baseline correction algorithms [30]. Often, the urea and water
peaks are combined into one exclusion region lying between 4.5ppm and 6ppm (default exclu-
sion region, but can be adjusted by the user). Excluding these areas of the spectrum helps
reduce sensitivity to artifacts.
Baseline Correction
It is easier to distinguish peaks in a spectrum when the baseline is featureless [72], however,
spectra can have distorted baselines due to imperfections in the detection process [75]. Curved
baselines can be a major source of error and so a correction is carried out on the raw spectrum
using a moving average [76]. This method involves splitting the data into windows of size
ω (default is 0.3125ppm), defined by the user, then using the median within the window to
estimate the baseline. In order to alter the baseline without losing metabolite peaks, a threshold
is set by dividing the maximum height by a user specified parameter (default is 10). All the
intensities found below this threshold are corrected by subtracting the estimated baseline.
Removal of Negative Artifacts
Negative artifacts, produced by baseline correction or simply inherent in the original spectrum
must be removed since their presence could interfere with peaks of interest in the mixture
spectrum. This is remedied by using an estimate of the noise standard deviation, σmed, to
calculate a limit value, l, using Equation 2.3:
l = M − 3σmed (2.3)
σmed is estimated by splitting the spectrum into a number of bins (given by the user, default
32) and calculating their standard deviations. The median of these standard deviations is used
as the estimate of σmed. M is the median of the intensities, yi. All intensities appearing below
this limit,l, are set equal to it.
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Kernel Smoothing
Noise from each standard metabolite spectrum will remain in the final mixture spectrum,
reducing the overall signal to noise ratio. Kernel smoothing is used to reduce the noise in each
individual metabolite spectrum. This process estimates the smooth function underlying the
noisy data using a weighted mean of surrounding data points with weights defined according to
the choice of kernel. Whilst the default kernel type is ‘Normal’, the user may also choose from
a number of options and also alter the bandwidth (given as number of data points), controlling
the degree of smoothing required. Since smoothing the whole spectrum would increase the peak
widths, only intensities below a user-defined threshold (a percentage of the maximum intensity,
default 0.8 %) are subject to kernel smoothing.
Peak Shift
If the user has chosen to simulate peak shifts (this is the default setting), these are then
calculated for each multiplet in each metabolite spectrum. First, a peak detection process is
used to identify peaks suitable for shifting. Peaks detected are cross-referenced with the HMDB
multiplet data to determine those belonging to a multiplet that must be shifted together.
Whether or not a peak is shifted depends on the user defined thresholds for peak detection,
and also its size relative to the noise. In real samples, peak positional variation can derive from
various matrix effects primarily pH differences but also due to variation in the concentration of
other ionic species in the mixture. In MetAssimulo, pH variation only is accounted for; this is
sufficient to produce very realistic shift patterns and avoids the need for many extra parameters
in the model. If pKa values and acid and base limits are not available, values are drawn from
normal distributions with user-specified mean and standard deviation. If the user requires the
same pH for all replicates of a mixture, the pH value is set as the user input. Otherwise, the
pH values are sampled from a normal distribution with mean and standard deviation defined
by the user. This information is then combined using the Henderson-Hasselbalch Equation [26]
(Equation 2.4) to calculate the peak shift (in ppm) and the peaks are shifted accordingly:
ηij =
10pH−pKaj(aij − δij) + (δij − bij)
10pH−pKaj + 1
(2.4)
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where δij is the un-shifted position of peak i of metabolite j in ppm (known), ηij is the amount
the peak is shifted in ppm (generated by Eq.2.4), pH is the pH of sample (simulated or input),
pKaj is the pKa of metabolite j (simulated or input) assumed here to be the same for all peaks
of a given metabolite, aij is the position of peak i of metabolite j in the acid limit (ppm)
(simulated or input), bij is the position of peak i of metabolite j in the basic limit (ppm)
(simulated or input). See Chapter 3 for more details on peak shift behaviour.
After this process, the spectrum is then smoothed again in order to suppress any unwanted
artifacts created by the peak shift.
2.1.3 Simulating Mixture Spectra
To make sure that all the metabolite spectra are on a comparable scale the spectra are nor-
malised to unit integrated intensity, using Equation 2.5:
yi =
y˜i∑n
i=1 y˜i
(2.5)
where y˜i is the intensity in the preprocessed, unnormalised standard spectrum.
Calculate noise standard deviation
The final mixture spectrum is constructed using Equation 2.1. The standard deviation σ of
noise to be added is calculated by dividing the maximum peak intensity by the signal to noise
ratio required by the user, SNR, as in Equation 2.6:
σ =
max(y(δ))
SNR
(2.6)
Even after preprocessing, the signal to noise levels of the individual metabolite spectra may
vary, so the final signal to noise ratio cannot be controlled perfectly. However, adding noise in
this way allows the simulation of mixture spectra with a wide variety of signal to noise ratios.
After adding the random noise, (δ) ∼ N(0, σ2), kernel smoothing is used on the composite
spectrum to reproduce the effect of apodization on real spectra [72].
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2.2 Results and Discussion
In this section some example outputs from MetAssimulo will be shown. Simulations of normal
urine were run using the optimized template with parameters set to the default values and
using the NSSD consisting of 48 spectra recorded at 600MHz 1H observation frequency.
Single Spectrum
To test whether MetAssimulo’s output spectra (Figure 2.2(a)) seem realistic they are compared
to a real normal human urine spectrum with the same exclusion regions (Figure 2.2(b)). It
should be noted that differences between real and simulated spectra will result not only from the
simulation process, but also from incomplete knowledge of the exact molecular species giving
rise to NMR signals and uncertainties in their levels. However, despite these difficulties, the
simulated and real spectra show many similarities including the dominance of high abundance
metabolites such as creatinine, glycine, and citric acid. The insets show how such realistic
simulation extends to low intensity signals of the aromatic region such as hippurate, histidine,
formate and N-methylnicotinic acid.
Figure 2.2: (a) Real normal urine 1H-NMR spectrum, (b) Mean of simulated normal urine
1H-NMR spectra produced using MetAssimulo.
Simulation of Case & Control Groups
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MetAssimulo can produce two groups of spectra with different metabolite compositions, illus-
trated here by simulation of spectra for both normal urine and a diseased state. Paraquat
poisoning [77] was chosen as the diseased state from several available in the HMDB, because
it shows a diverse array of metabolic disregulation in comparison with normal urine. The
concentrations of 4 metabolites are altered: citric acid and creatinine are decreased, whilst
alanine and lactic acid are increased. Simulations were run for 50 replicates of normal and
diseased without peak shifts, the mean of which are shown in Figure 2.3. These spectra clearly
show the expected decrease in citric acid and creatinine concentrations for Paraquat poisoning,
whilst alanine and lactate concentrations are increased. The PCA scores plot in Figure 2.4(a)
clearly demonstrates separation in the first principal component. The first and second principal
components (PC1 and PC2) explain 87.5% and 7.0565% of the dataset variance. The largest
loadings on PC1, Figure 2.4(b), correspond to the metabolites that were altered, accurately
describing the difference between the two groups. The largest loading on PC2 corresponds to
glycine, the metabolite with the highest within-group variance. This data could be used in
disease diagnostics to help train machine learning methods in recognising disease status.
Peak Shifts
Peak shift is demonstrated using histidine, a metabolite particularly prone to this kind of
positional variation. Acid and base limits were estimated by inspecting spectra taken at varying
pH values. Figure 2.5 clearly shows a shift in ppm values for this peak consistent with the non-
linear mechanism described by the Henderson-Hasselbach Equation 2.4.
Inter-Metabolite Correlations
To demonstrate the incorporation of inter-metabolite correlations, the pairwise Pearson cor-
relations of three metabolites: citrate, creatinine and 2-oxoglutarate are specified. Figure 2.6
shows the correlation matrix used.
This resulted in a positive definite covariance matrix, so no adjustments were required. Figure
2.7(i) visualises the correlation matrix between all spectral intensities. Most correlations are
close to zero as expected. The regions enlarged in (ii)-(v) illustrate the the correlations that
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were expected. The correlations can also be viewed in Figure 2.8 when the mean spectrum
is coloured according to the correlation coefficient with respect to a specified chemical shift
corresponding to a particular metabolite peak position ((a) citrate-2.65ppm, (b) creatinine-
4.08ppm, (c) 2-oxoglutarate-2.44ppm). Note that these analyses are similar to the commonly
used STOCSY [31] technique which is used to analyse both inter- and intra-metabolite corre-
lations; our simulations could be used to develop and test such methods.
2.3 Conclusion
There are currently simulation programs in different areas of post-genomic science, such as
SNP simulators that are being used in whole genome association studies [78, 79]. MetAssimulo
is a valuable addition to these tools, enabling the simulation of realistic 1H NMR spectra of
complex biological mixtures including group-wise variation, intermetabolite correlations and
peak positional variation. However, there are areas which could be enhanced. Any simulator
of this kind is limited by the sources of data available. The HMDB only contains information
about metabolite concentrations in humans, therefore further user input or other metabolite
databases may be needed to address other organisms. Human urine is the default setting for
MetAssimulo, but given the numerous alterable parameters, it is easy to simulate profiles for
other species and biofluids.
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Figure 2.3: (a) Mean simulated normal urine 1H-NMR spectrum, (b) Mean simulated 1H-NMR
spectrum of urine in paraquat poisoning produced using MetAssimulo.
Figure 2.4: (a) PCA scores plot of the first two principal components for the simulated normal
and diseased datasets show clear separation, (b) Loadings on PC1 indicating metabolite reso-
nances that describe a large portion of the difference between the normal and diseased datasets,
(c) Loadings on PC2 indicating metabolite that has a large within-group variance.
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Figure 2.5: Simulated 1H-NMR spectral peak shift for the two aromatic singlets of histidine.
Figure 2.6: Correlation matrix used to demonstrate MetAssimulo correlation functionality.
Figure 2.7: Inter and intra-metabolite correlations: (i) Complete correlation matrix and insets
(ii)-(v) showing strong negative inter-metabolite correlation between citrate and creatinine and
positive between 2-oxoglutarate and creatinine (ii),(iii) and strong positive intra-metabolite
correlations for creatinine (iv) and citrate (v). Colour scale indicates the level of Pearson
correlation.
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Figure 2.8: Pairwise correlation coefficients mapped as a colour code onto the mean spectrum.
Correlations to (a) citrate 2.65ppm, (b) creatinine 4.08ppm, (c) 2-oxoglutarate 2.44ppm.
Chapter 3
Modelling pH-induced changes in
1H-NMR chemical shifts
3.1 Background
Uncontrolled variation in chemical shift position of NMR resonances is a major challenge in sta-
tistical analysis of complex mixtures and greatly complicates signal deconvolution and metabo-
lite identification. Characterising this variation is an ongoing problem within metabolomics,
and there are several strategies available such as potentiometric titrimetry, UV spectrophotrom-
etry or capillary zone electrophoresis can be used to experimentally measure pKa values, but
NMR is by far the most common within metabolomics [80, 81, 82, 83]. NMR pH titration
involves measuring the chemical shift of an analyte at varying pH values, resulting in titration
curves mapping the relationship between chemical shift and pH.
There exists much literature detailing the derivation of 1H-NMR peak shift parameters of par-
ticular metabolites [84, 85, 86, 87]. Knowing these parameters is very useful in aiding peak
deconvolution methods such as BATMAN [60] and metabolite identification in addition to
furthering fundamental chemical knowledge. Also, by enabling improved deconvolution more
reliable chemical shift data will become available allowing us to model the parameters of these
complex peak patterns, continually improving our characterisation of the data. Improved es-
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timates are also highly beneficial in producing realistic simulation techniques. For example,
MetAssimulo (described in Chapter 2) uses this information to model realistic peak shifts de-
pending on the desired mixture pH [65]. With this motivation in mind, the positional variation
due to pH changes of several peaks is modelled with the aim of providing realistic estimates of
the parameters involved.
3.1.1 Modelling Titration Curves
Protonation is the fundamental reaction of adding a proton (H+) to a molecule. The protonated
and deprotonated species of a particular molecule will have different chemical shifts and a
molecule may have multiple sites where it is possible to bind this extra proton. The simplest
case is when a molecule A has a single protonation site - the monoprotic case. In the fast-
exchange regime the rate constant (speed of reaction) of the exchange process between the
different states or species is much larger than the difference in chemical shift between the states.
In this setting, a common resonance, δobsd, of two species (the protonated and unprotonated
versions of the molecule: HA+ and A ) can be represented by the weighted average of δA and
δHA, the limiting chemical shifts [84]:
δobsd = δA
[A]
[A] + [HA+]
+ δHA
[HA+]
[A] + [HA+]
(3.1)
where [A] denotes the concentration of molecule A. Using the definitions of the acid dissociation
constant, pKa, and pH given by Equations 3.2-3.4:
pH = −log10[H+] (3.2)
pKa = −log10Ka (3.3)
Ka =
[H+][A]
[HA+]
(3.4)
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and substituting into Equation 3.1 the Henderson Hasselbach Equation is obtained:
δobsd =
10pH−pKaδA + δHA
1 + 10pH−pKa
(3.5)
The pKa of an acid explains how acidic a particular hydrogen atom in a molecule is, whereas
pH is a measure of how acidic a solution is. pKa is the pH at which it is exactly half dissociated
[88]: the inflection point of the titration curve (see Figure 3.1 for a monoprotic example). It is
at this point that the concentrations of the acid and base conjugates are in equilibrium. The
acid/base chemical shift limits can be seen as the asymptotes of the curve at the two extreme
pH values.
Figure 3.1: An example monoprotic titration curve modeled by the Henderson Hasselbach
Equation is shown in blue. The pKa value is 7 and the inflection point is indicated with a black
cross. The acid and base asymptotic limits are given by cyan and red dashed lines respectively.
There are several approaches to modelling 1H-NMR titration curves. For example, the modified
Hill Equation:
δobsd = δA[1 + 10
n(pKa−pH)]−1 + δHA{1− [1 + 10n(pKa−pH)]−1} (3.6)
first presented by Markley [89], is often used as an alternative to the Henderson Hasselbach
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when the titration curve appears irregular or deviates from a single ionization equilibrium
[90, 87]. However, n, the Hill coefficient, can be difficult to interpret. Equally, one can use the
system of dissociation equilibrium equations exploiting the stoichiometry of the protonation
process [91, 92, 93].
When dealing with polyprotic cases, i.e. single titration curves with multiple equilibria, the
situation becomes more complex. Each equilibrium has its own pKa value and acid/base limits
shared with the adjacent equilibria, increasing the number of unknown variables. It can be
useful to investigate the equilibria at the microscopic level by examining the relations between
microconstants and macroconstants (pKa values) [94, 95, 96, 84]. However, since the number
of unknowns in the system increases for higher numbers of sites, the titration curves are split
into separate curves each containing a single equilibrium if possible. If adjacent equilibria are
a significant distance apart, i.e. at least four covalent bonds which corresponds to a difference
in pKa value of about 3 or more, the equilibria can be separated and modelled as individual
Henderson Hasselbachs [84]. Indeed, a common technique is to model polyprotic systems using
a mixture of Henderson Hasselbach Equations [94, 97].
An alternative to a Henderson Hasselbach mixture is an equation described by Szakacs (Equa-
tion 3.7) [98]. This approach generalises Equation 3.1 for an arbitrary number of protonation
sites (q) and reduces to the Henderson Hasselbach Equation for q = 1:
δobsd =
δA + Σ
q
i=1δHiA10
(Σqj=q−i+1pKaj)−ipH
1 + Σqk=110
(Σql=q−k+1pKal)−kpH
(3.7)
The values (pKa1, ..., pKaq) denote the pKa values associated with each of the q equilibrium
points and (δA, δH1A, ..., δHqA) are the relevant chemical shift limits. An example titration curve
for the polyprotic model with q = 2 is shown in Figure 3.2.
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Figure 3.2: An example polyprotic titration curve model for a two site molecule is shown in
blue. The pKa values are 3 and 8 with the inflection points indicated by black crosses. The
acid/base asymptotic limits are given by cyan, green and red dashed lines.
3.1.2 Model Selection Criteria
It would be useful to be able to predict the number of sites the metabolite has using the
titration curves. To this end, a reliable method of selecting the (polyprotic) model with the
correct number of sites is required. There are several strategies available for model selection
and here some of them are examined.
Akaike Information Criterion
The Akaike Information Criterion (AIC) was developed by Akaike in 1974 as a measure of the
goodness of fit of models [99]. It is calculated using the equation:
AIC = −2 · lnL+ 2 · k (3.8)
where L is the likelihood evaluated at the maximum and k is the number of free parameters
within the model. The AIC aims to strike a balance between the accuracy and complexity of
the model by penalising the likelihood by the number of parameters of the model and as such
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the smallest value indicates the best model. AIC may be preferred if the main application of
the model is prediction, whereas in cases where the primary goal is description (i.e. building a
model incorporating the most influential variables) one may opt for the Bayesian Information
Criterion.
Bayesian Information Criterion
Similarly constructed to the AIC, the Bayesian Information Criterion (BIC) developed by
Schwarz in 1978 [100] is:
−2 · ln p(y|k) ≈ BIC = −2 · lnL+ k · ln(n) (3.9)
where y = (y1, ..., yn) is the observed data and n is the sample size. Again, the smallest value
indicates the best model as one attempts to select the model corresponding to the highest
posterior probability. BIC uses the same goodness-of-fit term as AIC, but it has been argued
that the BIC penalises over-fitting more effectively than the AIC measure [101]. Under certain
settings the BIC is also roughly equivalent to selection using Bayes Factors, so has appeal in
problems where priors are hard to define accurately.
Deviance Information Criterion
The Deviance Information Criterion (DIC) is described as a hierarchical modelling generalisa-
tion of the AIC and BIC and is defined as:
DIC = pD + D¯ (3.10)
pD = D¯ −D(θ¯) (3.11)
D¯ = Eθ[D(θ)] (3.12)
D(θ) = −2 log(p(y|θ)) + C (3.13)
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where C is a constant that cancels in all calculations comparing models. D(θ) is defined as
the deviance and the expectation of this quantity, D¯, gives a measure of goodness of fit. pD
is the number of effective parameters of the model, whilst θ¯ is the posterior expectation of θ
[55, 102]. Here, again the smallest value is preferred for the best model. One major advantage
of DIC is that it is easily computed from MCMC output. However, the observed data is used
in constructing the posterior distribution as well as evaluating the candidate models so DIC
may have a tendency to promote over-fitting.
Log Pseudo Marginal Likelihood
The Log Pseudo Marginal Likelihood (LPML) is a summary statistic calculated from the Con-
ditional Posterior Ordinate (CPO) values using the harmonic mean [103, 104]:
LPML = Σni=1 log(CPOi) (3.14)
where
CPOi = p(yi|y[i]) =
∫
p(yi|θ)p(θ|y[i])dθ (3.15)
and y[i] denotes y with the i-th value eliminated. The CPO can also be described as the ‘leave-
one-out cross-validation predictive density’ and has been proposed as an alternative to model
selection techniques that employ a ‘double-use’ of the data. The CPOi values can be estimated
from MCMC output using the following formula [105]:
ˆCPOi =
1
T−1ΣTt=1p(yi|θ(t))− 1
(3.16)
where θ(t) denotes MCMC iterations from t = 1, .., T . CPO can be considered as the posterior
probability of observing yi when the model is fitted to all the data with yi omitted. Small
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values of CPOi are often used to detect outliers, and larger values of the LPML indicate a
better model fit. A ratio of pseudo marginal likelihoods is often considered as a surrogate for
the Bayes Factor, which can often be difficult to calculate exactly for complex models, and may
be described as the ‘pseudo Bayes factor’.
Bayes Factors
Bayes Factors are a standard method for Bayesian model comparison defined as the ratio of
the marginal likelihood under one model, say M1, to the marginal likelihood under the second
model M2 [55] :
p(y|M2)
p(y|M1) (3.17)
Values greater than 10 are considered substantial evidence supporting M1 and by similarly
values less than 1/10 support M2. Bayes Factors are considered to penalise model complexity
more effectively than the other methods outlined here and thus should have less tendency to
choose over-fitted models.
p(y|Mi) can be estimated from MCMC output in a variety of ways [101], but here a method
involving importance sampling is employed. The importance sampling estimate centres around
the identity:
1 =
∫
p(y)p(θ|y)
p(y|θ)p(θ) g(θ)dθ (3.18)
which gives the approximation:
pˆ(y)−1 = T−1ΣTt=1
g(t)
p(y|θ(t))p(θ(t)) (3.19)
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where θ(t) denotes MCMC iterations from t = 1, .., T , and g(t) denotes T samples from the
importance sampling function g. An importance sampling function taken from Newton &
Raftery based on combining samples from both the prior and posterior [106] is utilised:
g(θ) = δp(θ) + (1− δ)p(θ|y) (3.20)
with 0 < δ < 1. As recommended by the literature δ = 0.05. From the same source, a
synthetic estimator is used that avoids sampling from the prior density, with the algorithmic
form detailed in the Appendix.
Likelihood Ratio Test
The Likelihood Ratio Test is a common frequentist method for model comparison, but men-
tioned here for contrast. It is assumed that the ratio of the likelihoods of two models ( M1 =null,
M2 =alternative) has a χ
2 distribution with degrees of freedom df2−df1 where dfi is the number
of parameters of model Mi and θ
∗ is the value at which the likelihood attains its maximum:
L =
p(y|θ∗,M1)
p(y|θ∗,M2) (3.21)
−2 ln(L) ∼ χ2df2−df1 (3.22)
There is no consideration to Bayesian prior probabilities here, but it could be used to compare
the frequentist version of a model. In contrast to the Bayesian perspective where we might
ask to what extent does the data support one model over the other, here we ask whether the
maximum likelihood of the alternative hypothesis is large enough to reject the null hypothesis.
Since Bayes Factors consider the marginal likelihoods (likelihood averaged over all possible
parameter values) they, unlike the frequentist likelihood comparison, do not rely on a single
set of parameter values. It could be said that the strength of evidence required to advocate
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a more complex model is greater in Bayesian analysis than frequentist since the analytical
paradigm incorporates parameter uncertainty in addition to the estimation uncertainty present
in frequentist analysis[107].
3.2 Data
A large urine sample from five different individuals was collected and pooled to obtain an
average representative human urine sample. In order to evaluate if altering the pH in the
urine samples resulted in a change in ionic concentration, the main metal ion concentrations
in urine (Ca2+, Mg2+, Na+ and K+) were measured with ion selective electrodes following
the adjustment of human urine with acid (HCl) and base (NaOH). Some changes in the metal
ion concentrations occurred at the extremes of pH and this effect was more pronounced for the
divalent ions Ca2+ and Mg2+, so it was felt important to remove these ions by treating the
urine with chelex resin.
Treating the urine with chelex resin did not significantly alter the metabolite composition of
human urine as seen by 1H NMR spectra, but both Ca2+ and Mg2+ ion concentrations were
reduced. It must be noted that neither Na+ nor K+ ions were removed by the chelex resin,
and in fact Na+ ions were slightly increased as they were displaced from the chelex resin by
the divalent ions. However, it was noted from the literature that the main ionic contributors
to NMR peak shifts were the divalent ions Ca2+ and Mg2+.
Spectra were acquired on a Bruker Avance DRX600 NMR spectrometer (Bruker BioSpin, Rhe-
instetten, Germany), with 1H frequency of 600 MHz. Samples were introduced with an auto-
matic sampler. A one-dimensional NOESY sequence was used for water suppression; data were
acquired into 64K data points over a spectral width of 12 KHz, with 8 dummy scans and 64
scans per sample. Spectra were processed in iNMR 3.4 (Nucleomatica, Molfetta, Italy). Fourier
transform of the free-induction decay was applied with a line broadening of 0.5Hz. Spectra were
manually phased and automated first order baseline correction was applied. Metabolites were
assigned using the Chenomx NMR Suite 5.1 (Chenomx, Inc., Edmonton, Alberta, Canada)
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relative to 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS).
Metabolite peak positions from the different samples were obtained using in-house Matlab
scripts, and appropriate chemical shifts were calculated for multiplets relative to DSS for the
metabolites shown in Figure 3.3 with the number of sites given in Table 3.1. All samples were
prepared and processed by Gregory Tredwell (Imperial College London, UK).
Figure 3.3: Metabolite 1H NMR titration curves showing varying effects of pH on several
different labelled metabolite resonances.
Metabolite No. of Sites
Formate 1
Tris 1
Imidazole 1 1
Imidazole 2 1
Alanine 2
Creatinine 1 2
Creatinine 2 2
Piperazine 2
Tartrate 2
Citrate 1 3
Citrate 2 3
Table 3.1: Number of protonation sites for each metabolite studied. Where multiple resonances
are used for a single metabolite these are labeled numerically.
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3.3 Model Construction
For a molecule with q protonation sites a non-linear regression model is constructed using
Equation 3.7. Treating the observed chemical shift for n different pH levels as our response
variable y = (y1, ..., yn), gives:
y|µ, σ2 ∼ N(µ(pH,pKa, δA, q), σ2) (3.23)
µi =
δA + Σ
q
m=1δHmA10
(Σqj=q−m+1pKaj)−mpHi
1 + Σqk=110
(Σql=q−k+1pKal)−kpHi
σ2 ∼ IG(α/2, β/2)
pKat ∼ U(0, 14) for t = 1, ..., q
δA ∼ U(0, 10)
δHtA ∼ U(0, 10) for t = 1, ..., q
where the covariates consist of known pH = (pH1, ..., pHn) and fixed q whilst the q pKa values,
pKa = (pKa1, ..., pKaq), and q+1 acid/base limits, δA = (δA, δH1A, ..., δHqA), for each equilibria
are assumed unknown. Uniform priors are assigned to each pKai and δA, δHiA as physiologically
speaking there should be no prior preference for particular values, and an Inverse-Gamma to
σ2 with parameters (α/2, β/2) for the convenience of conjugacy. The pKa values are restricted
to ascending order within the interval [0,14] given that is the range of the pH scale, whilst the
δA values are allowed to vary freely over the NMR ppm scale [0,10]. Is it assumed that there
are no additional spectral effects.
3.3.1 Model Tuning and Convergence
Let us investigate model convergence for Imidazole 1, one of the chemical shifts of a one site
molecule using the one site model.
3.3. Model Construction 49
Figure 3.4: Metabolite 1H NMR titration curve for Imidazole 1 (a one site molecule with pKa
= 6.95)
The Imidazole curve has a single inflexion point at pKa = 6.95 and the chemical shift varies
between 7.13 and 7.48 for this titration experiment. Figure 3.5 shows a trace plot and density
of the pKa sampling for a run of 100,000 iterations of four chains with a burn-in of 100,000
and thinning parameter of 10 in rjags.
Figure 3.5: MCMC trace and density plot for pKa of Imidazole using 1 site model. 4 chains
run with 100,000 iterations after a burn-in of 100,000 and thinning parameter of 10.
The trace shows that the sampler quickly converges towards the stationary distribution and the
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density looks nicely normal with a mean of 7.09. Figure 3.6 shows the trace and density for the
acid and base limits. There does not seem to be strong convergence in the trace plots, indeed
the separate chains are not particularly correlated and the densities are multimodal. The acid
and base limit sampling is highly correlated and the model has difficulty with estimating these
variables.
Re-running with many more iterations, 500,000 iterations after a burn-in period of 500,000
iterations and increasing the thinning parameter to 100 does not improve the situation as
shown in Figure 3.7.
Figure 3.6: MCMC trace and density plot for acid and base limits of Imidazole using 1 site
model. 4 chains run with 100,000 iterations after a burn-in of 100,000 and thinning parameter
of 10.
A stronger prior on both acid and base limits was investigated to help improve convergence: a
truncated Normal distribution centred at the midpoint between 0 and 10 with variance of 1:
δA ∼ N(5, 1)I(0, 10)
δHA ∼ N(5, 1)I(0, 10) (3.24)
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Figure 3.7: MCMC trace and density plot for acid and base limits of Imidazole using 1 site
model. 4 chains run with 500,000 iterations after a burn-in of 500,000 and thinning parameter
of 100.
although physiologically speaking we should not prefer any particular ppm region to another.
Figure 3.8: MCMC trace and density plot for acid and base limits of Imidazole using 1 site
model with prior N(5,1)I(0,10). Multiple chains run for 100,000 iterations after a burn-in of
100,000 and thinning parameter of 10.
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Figure 3.9: MCMC trace and density plot for acid and base limits of Imidazole using 1 site
model with prior N(5,1)I(0,10). Multiple chains run for 500,000 iterations after a burn-in of
500,000 and thinning parameter of 50.
Figure 3.8 shows traces and density for multiple chains run with the stronger prior. Although
the density is now uni-modal, the distribution is quite strongly influenced by the mean of the
prior distribution. Increasing the thinning parameter to 50 and running longer burn-in (500,000
iterations) results in a better trace plot although the posterior distribution is skewed toward
the prior mean shown in Figure 3.9.
Since the prior distribution now seems too strong given the skew towards 5, we increase the
variance of the prior:
δA ∼ N(5, 2)I(0, 10)
δHA ∼ N(5, 2)I(0, 10) (3.25)
The resulting sample density is still too strongly influenced by the prior mean seen in Figure
3.10.
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Figure 3.10: MCMC trace and density plot for acid and base limits of Imidazole using 1 site
model with prior N(5,2)I(0,10). 4 chains run for 100,000 iterations after a burn-in of 100,000
and thinning parameter of 10.
The analysis is very sensitive to prior specification as it does not appear that there is enough
information in the data to estimate all the parameters. Analysis will be continued using the
original uniform prior distribution on the acid/base limits.
Let us examine the convergence of the two site model for a two site molecule chemical shift:
Piperazine, where the true pKa values are 5.56 and 9.83.
Figure 3.11 shows nice convergence in the trace plots with unimodal posterior distributions
centred close to the true values. Looking at Figure 3.12 we have a similar indentifiability issue
as for the one site model.
So again the stronger prior, N(5,1)I(0,10), is used with results shown in Figure 3.13. Similarly
for the one site model, this does slightly improve the performance of the sampling although
mixing does not seem optimal. Despite the issue of acid and base limit parameter identifiability
I explore the model further to investigate whether or not we can still garner useful information
about the molecular structure of the metabolite from the titration curves.
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Figure 3.11: MCMC trace and density plot for pka of Piperazine using 2 site model. 4 chains
run for 100,000 iterations after a burn-in of 100,000 and thinning parameter of 10.
3.3.2 Model Selection
Figure 3.14 shows our fit for three different metabolites: Formate, Creatinine and Citrate which
have 1, 2 and 3 sites respectively.
The plots show generally good fits for the data, which is contained within the 95% credible inter-
vals. The fits are also compared with a non-linear least-squares fitting algorithm in MATLAB
called nlinfit in Figure 3.15. Posterior estimates and variances of pKa values were calculated
using JAGS (Just Another Gibbs Sampler) via the R package rjags [59] and are shown in Table
3.2 alongside nlinfit with mean squared errors. It should be noted that frequentist and Bayesian
measures of uncertainty (i.e. mean square error vs posterior parameter variance) are conceptu-
ally different and therefore not directly comparable but I have included the nlinfit MSE here
for illustration to show that the titration curves can be very closely fit by the chosen function.
A number of different model selection criteria were investigated, focusing on the 1, 2 and 3 site
models.
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Figure 3.12: MCMC trace and density plot for acid and base limits of Piperazine using 2 site
model. 4 chains run for 100,000 iterations after a burn-in of 100,000 and thinning parameter
of 10.
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Figure 3.13: MCMC trace and density plot for acid and base limits of Piperazine using 2 site
model with stronger prior N(5,2)I(0,10). 4 chains run for 100,000 iterations after a burn-in of
100,000 and thinning parameter of 10.
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Actual Posterior Posterior nlinfit nlinfit
Metabolite pKa pKa Mean pKa Variance pKa Estimate MSE
Formate 3.77 3.51 0.020 3.56 2.4E-6
Tris 8.30 8.36 0.016 8.36 1.1E-4
Imidazole 1 6.95 7.09 0.016 7.09 8.0E-5
Imidazole 2 6.95 7.10 0.012 7.10 6.5E-5
Alanine 2.35 2.87 6.36 2.39 8.7E-4
9.69 10.68 1.41 9.98 2.0E-5
Creatinine 1 4.84 2.75 2.34 4.89 8.4E-6
9.2 8.76 4.30 11.30 0.02
Creatinine 2 4.84 3.06 2.14 4.89 5.0E-6
9.2 9.17 4.21 12.10 0.24
Piperazine 5.56 5.80 0.13 5.79 9.2E-5
9.83 10.11 0.19 10.10 1.8E-4
Tartrate 2.98 1.56 1.16 2.90 1.3E-4
4.34 5.35 3.93 3.97 7.3E-5
Citrate 1 3.09 1.06 1.25 2.94 2.0E-5
4.75 3.69 3.00 4.29 7.6E-5
5.41 8.3 4.32 5.48 2.7E-5
Citrate 2 3.09 3.53 5.14 2.94 0.001
4.75 7.08 36.25 6.02 0.003
5.41 13.47 0.73 5.51 2.5E-4
Table 3.2: Actual pKa values vs Posterior Mean pKa Estimates and Variance from MCMC
simulation using rjags package and MATLAB function nlinfit pKa Estimates with mean squared
error (MSE) values.
Metabolite Actual Sites 1 Site Model 2 Site Model 3 Site Model
Formate 1 -671.8 -679.3 -724.9
Tris 1 -449.6 -610.0 -609.8
Imidazole 1 1 -422.7 -563.6 -618.6
Imidazole 2 1 -334.7 -488.0 -517.4
Alanine 2 -275.3 -532.1 -528.2
Creatinine 1 2 -566.9 -566.4 -664.5
Creatinine 2 2 -561.3 -557.9 -603.0
Piperazine 2 -78.4 -390.8 -482.1
Tartrate 2 -382.3 -654.7 -662.1
Citrate 1 3 -247.3 -444.1 -738.0
Citrate 2 3 -269.5 -468.6 -590.1
Table 3.3: Akaike Information Criterion values for 1, 2 and 3 Site Models fitted to all the
metabolites, alongside actual number of sites of each molecule. Smallest values are shown in
bold, indicating chosen model.
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Metabolite Actual Sites 1 Site Model 2 Site Model 3 Site Model
Formate 1 -664 -668 -709
Tris 1 -442 -598 -594
Imidazole 1 1 -415 -552 -603
Imidazole 2 1 -327 -476 -502
Alanine 2 -268 -521 -513
Creatinine 1 2 -559 -555 -649
Creatinine 2 2 -554 -546 -588
Piperazine 2 -71 -379 -467
Tartrate 2 -375 -644 -647
Citrate 1 3 -240 -432 -723
Citrate 2 3 -262 -457 -575
Table 3.4: Bayesian Information Criterion values for 1, 2 and 3 Site Models fitted to all the
metabolites, alongside actual number of sites of each molecule. Smallest values are shown in
bold, indicating chosen model.
Metabolite Actual Sites 1 Site Model 2 Site Model 3 Site Model
Formate 1 -170.4 -177.3 -175.9
Tris 1 -170.6 -177.2 -175.6
Imidazole 1 1 -170.6 -177.0 -175.7
Imidazole 2 1 -169.4 -175.8 -174.2
Alanine 2 -166.1 -174.5 -174.5
Creatinine 1 2 -166.7 -175.7 -173.9
Creatinine 2 2 -170.8 -177.0 -176.0
Piperazine 2 -74.6 -173.0 -170.7
Tartrate 2 -155.7 -162.6 -162.3
Citrate 1 3 -162.4 -171.1 170.3
Citrate 2 3 -165.2 -173.1 -172.2
Table 3.5: Deviance Information Criterion values for 1, 2 and 3 Site Models fitted to all the
metabolites, alongside actual number of sites of each molecule. Smallest values are shown in
bold, indicating chosen model.
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Metabolite Actual No. 1 Site 2 Site 3 Site
of Params. Model pD Model pD Model pD
Formate 4 4.2 4.8 5.3
Tris 4 4.2 5.0 5.5
Imidazole 1 4 4.1 4.9 5.4
Imidazole 2 4 4.128 5.0 5.5
Alanine 6 4.2 5.4 5.7
Creatinine 1 6 5.3 5.3 5.9
Creatinine 2 6 4.1 4.9 5.4
Piperazine 6 5.1 6.3 7.0
Tartrate 6 4.6 5.1 5.2
Citrate 1 8 4.7 5.9 6.3
Citrate 2 8 4.6 5.6 6.0
Table 3.6: Actual number of free parameters for appropriate model and pD values (estimated
number of effective parameters) for each model.
Metabolite Actual Sites 1 Site Model 2 Site Model 3 Site Model
Formate 1 86.97 90.50 89.92
Tris 1 87.07 90.57 90.17
Imidazole 1 1 86.95 90.50 90.11
Imidazole 2 1 86.50 89.83 89.43
Alanine 2 84.65 89.01 88.97
Creatinine 1 2 85.21 89.16 89.85
Creatinine 2 2 87.08 90.76 90.18
Piperazine 2 38.50 89.03 88.20
Tartrate 2 79.50 83.21 82.77
Citrate 1 3 83.07 88.07 87.51
Citrate 2 3 84.45 88.97 88.66
Table 3.7: Log Pseudo Marginal Likelihood values for 1, 2 and 3 Site Models fitted to all the
metabolites, alongside actual number of sites of each molecule. Largest values are shown in
bold, indicating chosen model.
Metabolite Actual Sites 1v2 1v3 2v3
Formate 1 0.03 0.05 1.74
Tris 1 0.04 0.05 1.29
Imidazole 1 1 0.03 0.06 1.70
Imidazole 2 1 0.04 0.08 1.72
Alanine 2 0.02 0.02 1.17
Creatinine 1 2 0.02 3E-3 0.14
Creatinine 2 2 0.03 0.04 1.57
Piperazine 2 3E-20 7E-20 2.26
Tartrate 2 0.03 0.04 1.39
Citrate 1 3 0.01 0.02 2.034
Citrate 2 3 0.02 0.02 1.29
Table 3.8: Bayes Factors calculated using approximate marginal likelihoods, and showing pref-
erence for either the 2 or 3 Site Models over the 1 Site Model.
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Figure 3.14: Polyprotic model fit for 1 Site molecule Formate (top), 2 Site molecule Creatinine
(middle) and 3 Site molecule Citrate (bottom). Model1, Model2 and Model3 are polyprotic
models with q = 1, 2, 3 sites respectively shown from left to right. The data is shown in blue,
the fit and 95% credible intervals are indicated by black lines.
Figure 3.15: nlinfit model fit for 1 Site molecule Formate (left), 2 Site molecule Creatinine
(middle) and 3 Site molecule Citrate (right) with data given in blue and the fit shown in black.
The fit is so close as to be barely distinguishable by eye.
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From Table 3.3, the AIC chooses the 3 Site Model regardless of the number of sites the metabo-
lite has, except for Tris and Alanine where the 2 Site Model is selected. This suggests that the
AIC does not penalise heavily enough on the number of parameters of the model. Similarly
the BIC values shown in Table 3.4, indicate that the 3 Site Model is the ‘best’ fit, whilst again
selecting the 2 Site Model for Tris and Alanine. It should be noted that AIC and BIC are
not comparisons of the full Bayesian model but rather comparisons of the ‘frequentist version’
of the models using likelihood maximisation. Looking at Table 3.5, the DIC clearly has diffi-
culty choosing between the three models which is reflected in the close values in the column
of the table. The 2 Site Model is most consistently selected, indicating that the DIC may be
penalising model complexity better than the AIC and BIC. However, looking at the estimate
for the number of effective parameters of the model in Table 3.6 it is evident that the DIC
method underestimates the number of parameters for the 2 and 3 Site Models suggesting the
additional variables are correlated. A q Site Model has 2q + 2 free parameters: q pKa values,
q + 1 acid/base limits and the variance of the Normal likelihood. The differences between the
LMPL values (Table 3.7) for each model are very small, showing that the LPML cannot really
distinguish between models. The Bayes Factors are shown in Table 3.8. For all the metabolites
there is some evidence to prefer either the 2 or 3 Site Model over the 1 Site Model and when
comparing the 2 and 3 site we often prefer the model with fewer parameters.
Inability to correctly identify the model complexity is likely due to the sub-optimal fit provided
by posterior parameter estimates symptomatic of the poor MCMC convergence in conjunction
with the fact that there is not enough information in the data to estimate all the parameters
unless we include further constraints.
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3.4 Additive Constant
In order to improve the model fit, an additive constant, C, is introduced to µ to incorporate
any additional unknown structured variance. So the q site model becomes:
y ∼ N(µ(pH,pKa, δA, σ2, q) (3.26)
µi =
δA + Σ
q
m=1δHmA10
(Σqj=q−m+1pKaj)−mpHi
1 + Σqk=110
(Σql=q−k+1pKal)−kpHi
+ C (3.27)
C ∼ N(0, t2)
t2 ∼ IG(2, 0.5) (3.28)
for i = 1, .., n pH titrations and the rest of the model remains unchanged. The posterior pKa
estimates are shown in Table 3.9.
Metabolite Actual pKa Posterior pKa Mean Posterior pKa Variance
Formate 3.77 3.56 0.36
Tris 8.3 8.36 0.26
Imidazole 1 6.95 7.09 0.17
Imidazole 2 6.95 7.10 0.062
Alanine 2.35 3.99 4.48
9.69 11.11 1.66
Creatinine 1 4.84 2.88 2.15
9.2 8.77 4.17
Creatinine 2 4.84 2.09 2.06
9.2 7.16 3.70
Piperazine 5.56 5.80 0.13
9.83 10.10 0.19
Tartrate 2.98 1.54 1.15
4.34 5.25 3.92
Citrate 1 3.09 1.11 1.29
4.75 3.94 3.16
5.41 8.94 4.31
Citrate 2 3.09 1.54 1.15
4.75 5.25 3.92
5.41 9.23 4.13
Table 3.9: Actual pKa values vs Posterior Mean pKa Estimates and Variance for model with
additive constant.
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3.4.1 Model Selection
Metabolite Actual Sites 1 Site Model 2 Site Model 3 Site Model
Formate 1 -669.8 -686.0 -722.9
Tris 1 -447.6 -608.0 -607.85
Imidazole 1 1 -420.7 -561.6 -616.5
Imidazole 2 1 -332.7 -486.0 -482.0
Alanine 2 -273.3 -530.1 -555.3
Creatinine 1 2 -564.9 -664.4 -666.2
Creatinine 2 2 -559.3 -561.7 -601.0
Piperazine 2 -76.4 -388.8 -480.2
Tartrate 2 -380.3 -652.7 -660.1
Citrate 1 3 -245.3 -442.1 -736.0
Citrate 2 3 -267.5 -466.6 -588.2
Table 3.10: Akaike Information Criterion values for 1, 2 and 3 Site Models fitted to all the
metabolites, alongside actual number of sites of each molecule. Smallest values are shown in
bold, indicating chosen model.
Metabolite Actual Sites 1 Site Model 2 Site Model 3 Site Model
Tris 1 -437.9 -594.4 -590.4
Imidazole 1 1 -411.0 -548.1 -599.2
Imidazole 2 1 -323.0 -472.4 -464.6
Formate 1 -660.1 -672.4 -705.5
Alanine 2 -263.6 -516.6 -537.9
Creatinine 1 2 -555.3 -650.8 -648.8
Creatinine 2 2 -549.7 -548.2 -583.6
Piperazine 2 -66.8 -375.2 -462.8
Tartrate 2 -370.9 -639.6 -643.2
Citrate 1 3 -235.6 -428.5 -718.6
Citrate 2 3 -257.8 -453.1 -570.8
Table 3.11: Bayesian Information Criterion values for 1, 2 and 3 Site Models fitted to all the
metabolites, alongside actual number of sites of each molecule. Smallest values are shown in
bold, indicating chosen model.
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Metabolite Actual Sites 1 Site Model 2 Site Model 3 Site Model
Tris 1 91.4 90.4 89.8
Imidazole 1 1 91.4 90.6 90.3
Imidazole 2 1 90.7 90.1 89.6
Formate 1 91.2 90.6 89.5
Alanine 2 88.6 89.9 89.5
Creatinine 1 2 89.9 90.2 88.1
Creatinine 2 2 91.5 90.8 90.2
Piperazine 2 38.6 89.1 88.4
Tartrate 2 91.2 83.4 83.2
Citrate 1 3 86.7 87.83 87.75
Citrate 2 3 88.4 88.5 87.0
Table 3.12: Log Pseudo Marginal Likelihood values for 1, 2 and 3 Site Models fitted to all the
metabolites, alongside actual number of sites of each molecule. Largest values are shown in
bold, indicating chosen model.
Metabolite Actual Sites 1v2 1v3 2v3
Tris 1 2.45 5.04 2.05
Imidazole 1 1 1.98 2.65 1.34
Imidazole 2 1 2.91 6.13 2.11
Formate 1 1.47 2.84 1.69
Alanine 2 0.40 0.61 1.54
Creatinine 1 2 1.50 2.70 1.80
Creatinine 2 2 2.16 3.94 1.82
Piperazine 2 2.81E-20 6.84E-20 2.43
Tartrate 2 0.029 0.031 1.06
Citrate 1 3 0.51 0.53 1.03
Citrate 2 3 2.12 2.20 1.03
Table 3.13: Bayes Factors calculated using approximate marginal likelihoods, and showing
preference for either the 2 or 3 Site Model.
Metabolite Actual Sites 1 Site Model 2 Site Model 3 Site Model
Tris 1 -179.3 -177.3 -175.5
Imidazole 1 1 -179.3 -177.0 -175.8
Imidazole 2 1 -179.3 -176.8 -175.6
Formate 1 -179.4 -175.7 -174.1
Alanine 2 -174 -174.1 -173.5
Creatinine 1 2 -176.3 -174.5 -174.6
Creatinine 2 2 -179.6 -177.5 -176
Piperazine 2 -74.75 -172.8 -170.7
Tartrate 2 -164.5 -163.1 -162.3
Citrate 1 3 -169.7 -171.5 -170.5
Citrate 2 3 -172.9 -173.2 -172.2
Table 3.14: Deviance Information Criterion values for 1, 2 and 3 Site Models fitted to all the
metabolites, alongside actual number of sites of each molecule. Smallest values are shown in
bold, indicating chosen model.
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Metabolite Actual No. 1 Site 2 Site 3 Site
of Params. Model pD Model pD Model pD
Tris 6 4.24 5.02 5.43
Imidazole 1 6 4.22 5.07 5.46
Imidazole 2 6 4.20 5.01 5.57
Formate 6 4.19 4.86 5.40
Alanine 8 4.18 5.53 5.88
Creatinine 1 8 5.19 5.73 5.71
Creatinine 2 8 4.14 4.86 5.36
Piperazine 8 5.13 6.28 7.00
Tartrate 8 4.42 4.92 5.11
Citrate 1 10 4.75 5.83 6.37
Citrate 2 10 4.63 5.58 6.03
Table 3.15: Actual number of free parameters for appropriate model and pD values (estimated
number of effective parameters) for each model.
Once again, AIC (Table 3.10), BIC (Table 3.11), and Bayes Factor (Table 3.13) struggle to
choose between the 2 Site and 3 Site Models, although the Bayes Factor seems to perform a
little better for the additive model, whilst LPML (Table 3.12) marginally prefers the 2 Site
Model. DIC (Table 3.14) now consistently selects the less complex models (1 Site Model for
all except Citrate 1 and 2 and Piperazine), and Table 3.15 shows the number of parameters
are still underestimated. Looking across the two sets of results we see that the 1 Site Additive
Model is generally preferred to the 2 Site Model (without additive constant) suggesting the
additive constant is compensating somewhat for the fact that the fit is not as good as perhaps
it could be.
3.5 Random Effects Model
Next, strength is borrowed across chemical shifts of the same metabolite to estimate the pKa
in an attempt to improve the accuracy of the pKa estimates and general model fit [98]. The
pKa value should be the same for all chemical shifts of the same metabolite so a random effects
term is used for the pKa mean, giving us the following model for a metabolite with S chemical
shifts:
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ys ∼ N(µs(pH,pKas, δAs , σ2s , q)) (3.29)
µs,i =
δAs + Σ
q
m=1δHs,mA10
(Σqj=q−m+1pKas,j)−mpHi
1 + Σqk=110
(Σql=q−k+1pKas,l)−kpHi
+ Cs (3.30)
(3.31)
for s = 1, .., S chemical shifts consisting of measurements at i = 1, .., n different pH values, where
µs = (µs,1, ..., µs,n) is the mean vector for the s-th chemical shift. pKas = (pKas,1, ..., pKas,q)
denotes the q pKa values and δAs = (δAs , δHs,1A, ..., δHs,qA) gives the q + 1 chemical shift limits
for the s-th chemical shift of the metabolite. Constructing prior distributions as before, gives:
σ2s ∼ IG(α/2, β/2) (3.32)
pKas,j ∼ N(Pj, 1)
Pj ∼ U(0, 14)
δAs ∼ U(0, 14)
δHs,jA ∼ U(0, 14)
Cs ∼ N(0, t2s)
t2s ∼ IG(2, 0.5)j = 1, .., q
s = 1, .., S
Three metabolites with two chemical shifts each were chosen for further investigation: Imida-
zole, Creatinine and Citrate with 1, 2 and 3 sites respectively. The posterior pKa estimates are
given in Table 3.16. As is clear from the table, there is no improvement in the estimates.
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Metabolite Actual Posterior Posterior
pKa pKa Mean pKa Variance
Imidazole 6.95 7.094842 0.5391012
Creatinine 4.84 2.370332 4.385893
9.2 8.091135 20.69006
Citrate 3.09 0.5457603 0.2978543
4.75 1.811553 2.346749
5.41 6.09283 10.55541
Table 3.16: Actual pKa values vs Posterior Mean pKa Estimates and Posterior pKa Variance
for Random Effects Model.
3.5.1 Model Selection
As can be seen in Table 3.17, the DIC selects the 1 Site Model for all three metabolites. Looking
at Table 3.18 it is clear that the number of free parameters is still not well estimated.
Metabolite 1 Site Model 2 Site Model 3 Site Model
Imidazole -386.3 -382.9 -381.6
Creatinine -385.9 -381.5 -380.4
Citrate -382.8 -380.6 -379.6
Table 3.17: Deviance Information Criterion values for 1, 2 and 3 Site Models fitted to all the
metabolites, alongside actual number of sites of each molecule. Smallest values are shown in
bold, indicating chosen model.
Metabolite Actual No. 1 Site 2 Site 3 Site
of Params. Model pD Model pD Model pD
Imidazole 13 9.258 10.46 10.86
Creatinine 18 9.297 10.64 10.93
Citrate 23 9.933 11.06 11.38
Table 3.18: Actual number of free parameters for appropriate model and pD values (estimated
number of effective parameters) for each model.
3.6 Conclusion
Whilst the polyprotic model provides a good fit to the titration curves and fair estimates of pKa
values, it is clear that several different model selection criteria all have difficulty in correctly
predicting the number of sites the metabolite has. The introduction of an additive constant did
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little to improve the accuracy of parameter estimates, and it still proved difficult to select the
correct model. The random effects model also showed no improvement in parameter estimation
or model selection. These results indicate that predicting the number of sites of a molecule
from its titration curve is a difficult problem needing much further investigation.
Chapter 4
LC-MS Processing
4.1 Background
In this chapter I review some of the challenges faced and methods used in LC-MS data pre-
processing and also outline some new strategies. Since LC-MS is a technique popular within
proteomics as well as metabolomics, some pre-processing techniques used across both fields are
examined. Given the nature of vast raw LC-MS datasets, most pre-processing algorithms first
chop the data into mass-to-charge ratio (m/z) bins and interpolate in the retention time (Rt)
dimension over equally spaced nodes. If more than one Rt data point is swallowed by a single
(m/z, Rt) bin, then either the largest of the intensities or the sum is used. The resulting dataset
can therefore be processed as a matrix of intensities. A by-product of binning is that the data
can be arranged into a series of ‘Extracted Ion Chromatograms’ (EICs). XCMS [46], a widely
used pre-processing package, scales these chromatograms by the largest peak resulting in a set
of ‘Extracted-Ion Base Peak Chromatogram’ (EIBPCs).
The following conceptual model of the chromatographic signal is common: yi(t) = b(t) + N ×
s(t) + (t) for i = 1, ..., n where b(t) is the baseline, s(t) is the true signal, N is a normalisation
factor and (t) is noise-primarily electronic resulting from the detector and dependent on t
(Retention Time) and n is the number of chromatograms [108]. This approach means that
pre-processing is performed on each EIC (or sometimes mass spectrum if the m/z dimension is
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processed first) individually rather than borrowing strength across both dimensions, although
there are several algorithms akin to 2-dimensional image processing that attempt to buck this
trend [3, 109, 110].
It is generally accepted that essential pre-processing steps are Retention Time correction (or
alignment), peak detection, noise reduction or background subtraction, peak quantification,
pattern detection and matching, which can be enhanced by combining replicate datasets to
improve SNR and also systematically characterising sources of variability [50]. There is some
debate as to the optimum order to perform these processes and also considerable variation
of methods used within each of them. For example, there is the question of whether to per-
form Retention Time alignment before or after peak detection since peaks positions could aid
alignment, whether to use the continuous signal or peak positions, whether or not the process
should be dependent on signal amplitude and if samples should be aligned to some pre-defined
alignment ‘template’ or to the mean of all the samples. Alignment across samples can take
a variety or forms, e.g. correlation optimised warping, vectorised peaks, (semi) supervised
alignment using non-linear regression models, hidden markov models, statistical alignment or
clustering [50, 111, 112, 113]. One of the most widely-used method is Correlated Optimised
Warping (COW) which performs a linear warp within a window in order to optimise overlap
whilst maintaining matched boundaries.
Filtering and background subtraction is either performed by subtracting a fitted, additive base-
line model (e.g. splines) or using digital filters to smooth and enhance the MS signal (e.g.
moving average, Savitsky-Golay, matched filtering etc.). These can be performed on one or
both of the dimensions (Rt or m/z) simultaneously, alternately or iteratively. There exist myr-
iad algorithms utilising different combinations of peak models and criteria, including searching
for signal maxima that coincide in both the m/z and Rt directions (vectorised peak detec-
tion) [114], intensity thresholding, examining the local neighbourhood of a candidate peak,
using wavelet decomposition to investigate scale-specific peaks, or curve resolution to extract
major spectral components [115, 116]. Often, signal filtering and background subtraction are
performed implicitly when detecting peaks.
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4.1.1 Wavelet Smoothing
Wavelets have become a popular choice of method for de-noising a variety of signals and are
becoming widely used within metabolomics. Wavelets are mathematical functions resembling
‘small waves’ and are particularly useful in image compression, where the resulting decomposi-
tion is often sparse. Wavelet decomposition is a multi-scale method, meaning the decomposition
consists of coefficients describing the data object at a range of dilations and positions of the
wavelet function used. The wavelet function is chosen to reflect the shape of wave characteristic
of the data (see Figure 4.1 for examples).
Figure 4.1: Examples of two commonly used wavelet functions (a) Daubechies 4, (b) Symmlet
8 [4]
Let ψa,b(t), a ∈ R+, b ∈ R, denote a family of wavelets consisting of translations and dilations
of a ‘mother wavelet’, ψ(t) ∈ L2(R) [117]:
ψa,b(t) =| a |−1/2 ψ(t− b
a
) (4.1)
For a function of finite energy, f , the Continuous Wavelet Transform is defined by Cf [118]:
Cf (a, b) =
∫
R
f(t)ψ¯a,b(t)dt (4.2)
where ψ¯ represents complex conjugation of ψ. The family of wavelets must satisfy the admissi-
bility condition, which specifies ψ(x) should be oscillatory and localised in time and frequency
in addition to integrating to zero:
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∫ ∞
−∞
| Ψ(ω) |2
| ω | dω <∞ (4.3)
where Ψ(ω) is the Fourier transform of ψ(t).
In order to reduce the redundancy of the transform, the values of a and b can be discretised
whilst retaining the invertibility of the transform. ‘Critical sampling’, or the finest scale possi-
ble, produces a basis on L2:
{ψj,k(t) = 2j/2ψ(2jt− k), j, k ∈ Z} (4.4)
a = 2−j
b = 2−jk
j, k ∈ Z
This convention enables implementation of the Discrete Wavelet Transform, a fast decomposi-
tion algorithm (see [4] for details). Decimation, which enables coarse wavelet coefficients to be
described as a convolution of finer scale coefficients can reduce redundancy further; however, the
Undecimated Discrete Wavelet Transform (UDWT) is often preferred since it is shift-invariant.
The wavelet coefficients of fine scales correspond to high frequency features in the original
signal, so these can be thresholded before performing the inverse transform. There are a
number of threshold methods available, each with specific advantages and disadvantages. The
main methods for applying a threshold λ are ‘soft’ (Equation 4.5) and ‘hard’ (Equation 4.6)
thresholding of a signal y(t):
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ysoft(t) =
 sign(y(t)) · (|y(t)| − λ) if |y(t)| > λ0, if |y(t)| < λ (4.5)
yhard(t) =
 y(t) if |y(t)| > λ0 if |y(t)| < λ (4.6)
where the function sign determines whether a value is positive or negative. When the wavelet
reconstruction is performed, the noise should be removed and the signal visibly cleaner.
4.1.2 Peak Detection
Here I discuss some of the most commonly used techniques for peak detection.
Vectorised Peak Detection
Perhaps the most intuitive way to distinguish analyte peaks from noise, is to look for peaks
that are local maxima in both the retention time dimension and the m/z dimension. This
approach is formalised by Hastings et al. [119], but many other peak detection algorithms use
this criterion in conjunction with others, e.g. MZmine also imposes specified peak widths [120].
An advantage of this simple technique are that points lying in ion chromatograms corrupted
by solvent clusters or column bleeds are only identified if they exceed a threshold defined by
the level of noise in that particular chromatogram, not adjacent ones.
Isotopic Pattern Matching
Whilst generally concerned with larger molecules (more typically within proteomics than metabolomics),
an interesting area of investigation is de-isotoping or charge deconvolution. This approach uses
the fact that isotopic peaks often appear in LC-MS data resulting from heavy isotopic variants
of carbon and other atoms, forming a predictable pattern [50]. Based on the mass differen-
tial, one can deduce the charge state of multiple charged ions and then compare with reference
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tables. However, this is difficult to perform on complex mixtures. There are several peak detec-
tion algorithms utilising isotopic pattern matching, for example VIPER [121, 122], MSInspect
[123], PEPLIST [124]. VIPER uses an isotopic pattern matching routine, THRASH, in con-
junction with a database of previously identified molecule positions [121, 122]. THRASH, like
most isotopic pattern matching algorithms, works by comparing an ‘expected isotope pattern’
to this observed isotopic cluster, and producing a ‘fitting score’. Methods for generating the
theoretical isotopic distribution vary, from using a Poisson distribution [123] to a model amino
acid ‘averagine’ (an ‘average’ amino acid calculated from occurences of amino acids in a protein
database) in proteomics applications [124].
Image Detection
Another area of research being exploited for methods applicable to LC-MS peak detection, is
mathematical morphology and image detection theory. Mathematical morphology is concerned
with the characterisation of geometric structures using set theory, lattice theory, topology and
random functions [125, 126, 127, 128]. Packages adopting these techniques, such as edge-
detection and segmentation functions, include MeDDL [109], DoGEX [110] and MapQuant [3].
Given the 2D nature of LC-MS data, it can be useful to visualise a sample as a heat map image,
where intensity defines colour. Indeed Du et al. (2007) have developed a supervised package,
LC-MS-2D [129], in order to take advantage of this fact.
Wavelets
There are several peak detection packages using wavelets in conjunction with other peak-picking
criteria or thresholding, or directly for peak picking themselves [123, 124, 130, 131, 132, 133].
For example, PrepMS [134] is a pre-processing package that de-noises MS spectra using an
undecimated wavelet transform as described by [108] and detects features using the mean spec-
trum as outlined by [135]. Also developed by Morris, is Pinnacle: a wavelet-based package for
detecting and quantifying protein spots. Gel-based electrophoresis used in proteomics creates
datasets that share some of the 2-D complexity of metabolomic LC-MS data. Morris de-noises
the average gel using wavelet shrinkage and hard thresholding. All peaks are detected from the
reconstructed signal and those within a given proximity of a higher intensity are then combined
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[136].
Figure 4.2: (a) Identified Peaks in m/z domain with SNR >3, (b) CWT coefficients of the signal
at different scales, (c) ’Ridge Lines’ constructed from joining the location of local maxima at
different scales and indicate where ’important’ features persist over multiple scales.[5]
By comparison, Du, W. et al. (2006) employs a continuous wavelet transform using the Mexican
Hat wavelet (Gaussian second-derivative) and identifies peaks by tracking the ‘ridge lines’ of
a colour-map representing wavelet coefficients at different scales (see Figure 4.2)[5]. Identified
peaks (ridge lines) can be further thresholded using the scale, SNR or ridge length.
Kalman Tracking
An example of digital filtering is the Kalman Tracking algorithm used by Aberg [137]. The
aim is to circumvent the problem of mass binning by tracking features in the two dimensional
plane. A centroid mode mass spectrum from one scan can be viewed as a set of points on a 2D
plane with m/z as x-axis, y-axis as intensity. The data will consist of structured signal which
should behave predictably, and random noise. Given this data structure it is possible to borrow
algorithms from tracking signals of objects, such as aircraft, in radar data. In constructing the
Kalman Filter, there are three considerations:
• Movement of the object, i.e. process uncertainty.
• Measurement uncertainty - variation resulting from imprecise measurement technique.
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• Noise - Random signal interference.
In the short term the object’s trajectory is expected to be smooth, with long term changes
in direction so search for an optimal filter for tracking an object with constant velocity in the
presence of random velocity changes between measurements. One has no knowledge before
measurements of how the object will manoeuvre. The structure of consecutive centroid mode
mass spectra (scans) can be related to radar scans where m/z, and intensity are linked to
azimuth (angle of trajectory) and range respectively.
Functional Mixed Models
Functional mixed models can identify differentially expressed regions possibly missed by peak
detection and can automatically adjust for nuisance factors [108, 138]. In [139, 140] Morris sets
out a novel way of investigating LC-MS data within a Bayesian framework. Functional mixed
modelling avoids reliance on peak detection methods whilst allowing flexibility and spatially
adaptive regularisation as well as being able to simultaneously model multiple effects. Some
pre-processing, baseline correction, normalisation, de-noising and possible transformation, may
be carried out prior to model fitting. Morris’ model is characterised by the following equation:
yi(t) = Σ
p
j=1XijVj(t) + Σ
m
k=1ZikUk(t) + Ei(t) (4.7)
U(t) ∼ N(0, Q) (4.8)
E(t) ∼ N(0, S) (4.9)
where yi, for i = 1, .., N , represent N functions (in this case MALDI-TOF spectra) defined over
the time axis t. (Xij) is the matrix of covariates, Vj for j = 1, ..., p the vector of p functional
fixed effects, (Zik) is the design matrix for the m functional random effects U(t) = (U1, ..., Um)
with covariance Q and E(t) = (E1, ..., En) with covariance S is the residual error. A discrete
matrix version of the model can be described and is fitted using a basis function approach,
using wavelet basis functions since they characterise the MS peaks well.
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The discrete wavelet transform (DWT) is applied to each of the N spectra, projecting the
observed data into the wavelet-spanned space. MCMC samples are obtained to the wavelet-
space version of the model which are then projected back to the data-space using the IDWT.
Bayesian inference can then be applied to these samples, for example posterior probabilities
of being a feature of interest can be computed for each peak, and a threshold of significance
determined.
Diffuse proper priors are specified for variance components and adaptively regularised repre-
sentations of the fixed effect functions Vj are obtained by utilising a multiple-shrinkage prior
on the wavelet coefficients for the fixed effects.
Combining Criteria
A number of LC-MS pre-processing packages, for example MZmine [120, 141], Yasui et al. [142],
PEPLIST [124], MSInspect [123], integrate two or more of the approaches mentioned above,
often combining peak criteria to give an overall ‘fitting score’. Some of the peak characteristics
may also be thresholded, for example peak intensity, peak length or shape (by fitting a function
such as a Gaussian) in one or both dimensions. One such package is MEND [143] which
incorporates matched filtering, vectorised peak detection and isotopic pattern matching. A
fitting score for each of the three characteristics is calculated and the scores are thresholded.
Full processing suites may also give access to a number of different techniques for each of the
pre-processing steps required (including peak detection) that can be performed separately or
together, for example MZmine. The more recent overhaul of MZmine resulted in a modular
package containing multiple methods for smoothing, peak detection, peak alignment, peak iden-
tification, normalisation, visualisation and other statistical analysis [141]. There are multiple
‘plug-in’ algorithms for peak detection including local maxima searching, a method based on
the mexican hat wavelet transform, SNR thresholding, filtration, LC peak length thresholding
and intensity thresholding.
Conclusion
The methods described in this section and Table 4.1 are by no means an exhaustive list, there
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has been much recent research into other multivariate approaches [115], second order methods
[144] and MCMC algorithms [145]; but Wavelets, Digital Filters, Isotopic Pattern Matching
and Image Processing techniques remain the more standard approaches.
Within proteomics applications [146] finds that Wavelet-based methods perform better than
other filters combined with more heuristic criteria for 1D MS peak detection. [147] also promotes
wavelet smoothing as characterising peaks shapes well since by smoothing over multiple scales
one avoids the problem of more traditional filters that use a fixed size window. By contrast,
[47] evaluates filters for smoothing in the chromatographic domain and finds that the filter
performance (measured by SNR) is very much dependant on data characteristics such as noise
level and type as well as peak size, shape and integrity. [45] reports that the best performing
algorithms for LC-MS are those that utilise both the m/z and Rt domains to locate features
and thus more fully exploit the 2-D nature of the data.
However, incorporating more prior knowledge about the data structure does not necessarily
result in a more effective algorithm. Packages based on simple intensity thresholding, for
example msInspect, have been shown to outperform those using more descriptive peak picking
criteria, such as MZmine. [41] shows how combining the intensity thresholding with other peak
picking criteria such as thresholding LC peak length or isotope pattern matching did nothing
to improve the performance. More complex LC peak filtering also underperformed compared to
the peak intensity-based method since the peaks are often poorly shaped and do not resemble
the traditional chromatographic peak models, such as Gaussian.
There exist many reviews documenting the abundant peak detection algorithms and methods
on offer but few articles that rigorously compare or critique their performance alongside each
other, particularly within the context of metabolomics data. Many of the algorithms were
initially designed to fulfil the particular analytical needs of a given lab ( i.e. specific LC-MS or
MS configuration, data format, bio-fluid/organism type, context of experiment and application
- perhaps proteomics rather than metabolomics etc.) and are later generalised or else are an
exploration of a particular statistical/modelling technique but not presented as part of a full
pre-processing tool. For those that are available as an end-to-end processing suite applicable
4.1. Background 79
across different (LC-)MS setups, comparison cannot necessarily be performed fairly given the
variability of algorithms employed for the other pre-processing steps such as retention time
alignment, de-noising etc. Peak detection performance may also depend on the order in which
the steps are executed and will often be inextricably coupled to one or more of these other steps
so cannot be compared in isolation. Both [41] and [50] mention the problem that many peak
detection algorithms are of a relatively ad-hoc nature and as such no single package seems to
offer a universally robust solution or one that does not require substantial parameter tuning.
Generally speaking, choice of peak detection method will depend on the instrument used (most
manufacturers also provide their own closed processing software specific to the machine), the
output data format (different software packages handle different file formats), characteristics
of the data (if background noise a particular problem for the experiment etc. it may need
an algorithm employing more aggressive smoothing techniques before peak detection than for
another experiment) and also personal preference of the person or lab where analysis is being
performed (the individual’s expertise may be within a particular statistical environment such
as R/MATLAB etc. or a tool may have been developed within the lab). Researchers may
also choose to run their data through multiple software to prevent feature loss that may occur
as a result of using a single algorithm, on the assumption that different approaches may be
complimentary and perhaps pick up aspects of the data that a different algorithm missed.
LC-MS technology is advancing at a rapid rate with instruments producing larger and more
complex datasets as a result of capability for much greater sensitivity and resolution. This in
itself poses a challenge as software and processing techniques must either evolve quickly to keep
up or be robust enough to cope with changing data characteristics.
Given the huge variability of a LC-MS dataset due to the multiple factors described, one could
argue that the more powerful techniques are those that are robust to changing noise levels, peak
size and shape and/or can self-learn the characteristics of the data it is processing. However,
there is useful information to be derived from knowing the configuration of the instrument used
and characteristics of the biofluid so perhaps more complete feature detection can be achieved
when the algorithm is finely tuned or even specifically designed to capture these nuances for
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a particular experimental set-up, or at least until machine learning algorithms can truly catch
up with the expertise of the researcher in recognising veritable features.
Package Platform Data Methods Ref.
apLC-MS LC-MS Metabolomics Adaptive Binning [66]
centWave LC-MS Both Wavelet Denoising [130]
DoGEX LC-MS Metabolomics Wavelet Denoising [110]
Image Detection
LC-MS-2D LC-MS Proteomics Isotope Pattern Matching [129]
MapQuand LC-MS Proteomics Matched Filtration [3]
Mathematical Morphology
MeDDL LC-MS Metabolomics Image Detection [109]
MEND LC-MS Proteomics Matched Filtration [143]
Isotope Pattern Matching
Vectorised Peak Detection
msInspect LC-MS Proteomics Local Maxima [123]
Isotope Pattern Matching
MZmine LC-MS Both Vectorised Peak Detection [120]
Image Detection
PepList LC-MS Proteomics Wavelet Denoising [124]
Isotope Pattern Matching
Pinnacle 2DE Proteomics Wavelet Denoising [140]
Mean Spectrum [135]
PrepMS TOF-MS Proteomics Wavelet Denoising [134]
Local Maxima
TracMass GC/LC-MS Metabolomics Kalman Tracking Filter [137]
VIPER LC-MS Proteomics (Rt, m/z) Tag Database [122]
Isotope Pattern Matching [121]
WaveletQuant LC-MS Proteomics Wavelet Denoising [132]
waveSpec MS Both Wavelet Denoising [148]
Kernel Density Estimation
wfmm Functional Both Wavelet-Based [140]
Data Functional Mixed Models [139]
XCMS LC-MS Metabolomics Matched Filtration or [46]
Wavelet Denoising
Befekadu et. al LC-MS Proteomics Functional Mixed Models [138]
Du, et. al SELDI Proteomics Wavelet Domain [5]
TOF MS Local Maxima
Hastings et. al LC-MS Both Vectorised Peak Detection [119]
Stolt et. al LC-MS Metabolomics Second Order Method [144]
Wang et. al SELDI-MS Proteomics Functional Mixed Models [145]
Table 4.1: Overview of existing pre-processing algorithms for (LC-)MS data.
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4.1.3 Data Binning
As technological advances allow us capability for higher resolution LC-MS data the problem of
data binning becomes ever more apparent. High resolution data files are extremely large and
unwieldy from a data analysis point of view, often containing a large proportion of chemical and
instrumental noise. Myriad smoothing and feature extraction algorithms have been developed
and this remains a thriving area of research. However, less literature is devoted to the problem
of data binning. It is an optimisation problem that is often overlooked in favour of uniformly
spaced bins of a size specified by the user. Peaks can drift in and out of bins if the bin size is too
small (see Figure 4.3), if a cut-off point intersects with a peak or, equally undesirable, multiple
peaks can be squashed into a single bin if the bin size is too large and information is lost.
Smaller bins create extra computations, but they are more likely to capture fewer peaks per
bin. Smith et al. [46] attempt to address this problem in XCMS by constructing overlapping
bins and filtering out duplicate peaks under supervision.
Figure 4.3: A chromatographic peak split across three bins due to drift in m/z.
Another package that attempts to tackle this is apLC-MS [66]. apLC-MS orders the data-
points by m/z value and then constructs a vector containing the differences between consecutive
points. A mixture model describing the differences in m/z value between and within peaks is
constructed to calculate an m/z threshold and the data grouped accordingly (described in
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further detail later in the chapter). Similarly to LC-MS, drift is also a problem within NMR
spectra and binning is often used in order to evaluate spectral density. Although this problem
is 1-Dimensional, Davis et.al [149] take an interesting approach using wavelets which is worth
noting. Similarly to the method used by Du et.al in centWave [5] for detecting maxima in
chromatograms, Davis uses a wavelet transform (undecimated, to avoid filter artifacts) but
detects minima in the wavelet domain instead. The aim is to identify minima that indicate the
beginning and end of each peak. In contrast to Du, Davis performs the transform at a single
level rather than linking minima across levels, with the appropriate level depending upon the
data resolution and typical peak width. In Section 4.3 I build on these methods to develop a
novel binning strategy as part of a new pre-processing algorithm, H-MS, but first a Bayesian
model for peak detection is explored.
4.2 A Bayesian Partition Model for Peak Detection
We propose a Bayesian strategy to analyse LC-MS peak distributions using a ‘Bayesian Parti-
tion Model’ (BPM) also known as a ‘Change Point Model’. The goal is to develop an LC-MS
algorithm that identifies co-eluting peaks that may belong to the same molecular species. To
this end, we will need to de-noise the data as well as identify and describe metabolite peaks as
accurately as possible.
BPMs have been employed increasingly in a variety of settings, from cosmology to economics
[150, 151, 152]. The model assumes that observations within a segment of a random partition
of the series follow the same distribution [153]. They were pioneered by Barry and Hartigan in
the 1990s and have since gained popularity in many fields [154, 155, 156, 157, 158, 159, 160].
Initially working on individual chromatograms, where the n observations are denoted by y =
(y1, ..., yn), a BPM is developed to characterise changes in signal level. This way, if each segment
follows a normal distribution with parameters dependent on the partition, a peak should be
‘detected’ as a segment with a mean level significantly different from zero. The change-points
τ = (τ1, ..., τk), specify the data-points at which a new segment of the partition begins. Each
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possible number of change-points, k, will have multiple change-point configurations. It is the
posterior distribution of the change-point locations that will tell us the most likely points at
which the mean signal level changes significantly thus identifying possible peak locations. We
denote the signal segments by Ri, defined by Equation 4.10:
Ri = {yj : j = τi−1 + 1, .., τi} for i = 2, .., k (4.10)
and R1 = {yj : j = 1, .., τ1}
Rk+1 = {yj : j = τn−1 + 1, .., n}
Let τ (k) be the set of all possible partitions over the locations {2, .., n−1} of size k ∈ {0, .., n−2}
change points. All possible partitions for a given k are equally likely so we assign a uniform
prior to τ (k). We also assign a truncated geometric prior to k:
p(τ (k), k) = p(τ (k) | k)p(k) (4.11)
p(τ (k)|k) =
(
n− 2
k
)−1
p(k) = (1− q)kqI(0, n− 2)
where q is a constant parameter. Given this partition, the likelihood is simply the product of
the likelihood for each of the k + 1 segments:
p(y | τ (k), k) =
k+1∏
i=1
p(yRi | τ (k), k) for yRi = {yi ∈ Ri} (4.12)
Likelihood
We assign yRi = {yj ∈ Ri} for i = 1, .., k + 1 a multivariate normal distribution:
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yRi | τ (k), k ∼ N(x′iµi, Iσ2i ) for i = 1, ..., k + 1 (4.13)
where yRi is a vector of length ni. x
′
i is the ‘design’ matrix, a 1×ni vector describing the shape
of the data. µi and σi are scalar parameters, whilst I is the appropriate identity matrix. For
computational simplicity, we will initially use a vector of 1’s for the design matrix.
Conjugate Prior
We assign conjugate a prior to µi as follows:
µi ∼ N(θi, piσ2i ) (4.14)
where the prior mean, θi, and precision, pi, are constants. Again, using conjugacy we have the
following prior for σi:
σ2i ∼ IG(
di
2
,
si
2
) (4.15)
where di
2
is the shape parameter and si
2
is the scale parameter.
Marginal Likelihood
Using a useful theorem for normal-normal models, given in Appendix .3, in conjunction with
another theorem for marginalising over µ we have:
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yRi | σi ∼ N(x′iθi, σ2i (pix′ixi + I)) (4.16)
i = 1, .., k + 1
For a normal-gamma model, a theorem from [55, 161] gives that the marginals over σ2 are given
by a multivariate Student t-distribution with ni dimensions and si degrees of freedom:
yRi | k, τ (k) ∼ Stdi(x′iθi,
si
di
(pix
′
ixi + I)) (4.17)
i = 1, ..., k + 1
Writing the marginal likelihood as a product of the probabilities within each region we have:
p(y | k, τ (k)) = Πk+1i=1 p(yRi | k, τ (k)) (4.18)
where
p(yRi | k, τ (k)) =
Γ(di+ni
2
)(1 + 1
di
(yRi − xiθi)′Σ−1i (yRi − xiθi))−
di+ni
2
Γ(di
2
)(dipi)
ni
2 | Σi | 12
(4.19)
and
Σi = (I + pix
′
ixi)
si
di
(4.20)
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Furthermore, the multivariate Student-t probability density function simplifies using the follow-
ing a result from [161], greatly increasing computational efficiency. Given observations y1, ..., yn
i.i.d as N(µi, φi) with the mean and variance unknown and using the conjugate prior, then
p(yRi | τ (k)) =
(2pi)−
ni
2 (ni + p
−1
i )
− 1
2 Γ
(
di+ni
2
) (
si
2
)di/2(
si+zi
2
) (di+ni)
2 Γ
(
di
2
) (4.21)
where
zi =
ni∑
j=1
(yj − y¯Ri)2 +
ni(y¯Ri − θi)2
pini + 1
(4.22)
and y¯Ri is the mean of y within region i. Although it is possible to calculate the posterior for k
analytically, it is computationally very intensive. Therefore, we prefer to sample from p(k | y)
with a Metropolis Hastings algorithm, using that:
p(k | y) ∝ p(y | τ (k), k)p(τ (k)|k)p(k)
∝
k+1∏
i=1
p(yRi | τ (k), k)p(τ (k)|k)p(k) (4.23)
Posterior Distribution given k and τk
Within a particular region, i, we have:
4.2. A Bayesian Partition Model for Peak Detection 87
σ2i | yRi ∼ IG(
d∗i
2
,
s∗i
2
) (4.24)
where d∗i = di + ni
s∗i = s+
1
2
(yRi − xRiθi)I−1(yRi − xRiθi)
Since xRi is a vector of 1’s, s
∗
i simplifies:
s∗i = si +
1
2
ni∑
j=1
(yj − θi)2 (4.25)
The posterior distribution for µi is given by the following:
µi | σ2i ,yRi ∼ N(m∗i , V ∗i ) (4.26)
V ∗i =
σ2i pi
1 + nipi
m∗i =
V ∗i
σ2i
(
θi
pi
+ x′RiyRi)
Similarly, m∗ simplifies:
m∗i =
θi + pi
∑ni
j=1 yj
1 + nipi
(4.27)
4.2.1 Metropolis-Hastings Algorithm for Multiple Change Points
The following algorithm is based on a modified version of the sampling procedure outlined in
[162]. This is a symmetric procedure so avoids the added complexity of calculating the proposal
correction.
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At iteration t, given kt−1 and τ t−1...
1. Draw a candidate point γ from the possible change point locations, {2, .., n− 1}.
2. If not a change point, γ becomes a change point and k increments by 1 to k∗, if already
a change point then remove it and k∗ = k − 1. Define τ ∗ as the new configuration of change
points including the alteration to γ. Calculate the acceptance ratio using Equation 4.28 and
update the current value of k and τ accordingly.
3. Draw a new random permutation of k change points, defining k∗ = k and τ ∗ is the new
change point configuration. Calculate acceptance ratio using Equation 4.28 with the new k and
τ of the previous step and update to kt and τ t accordingly.
The acceptance ratio for an update from k and τ to a proposed k∗ and τ ∗ is defined as:
r = min{1, p(y|τ
∗, k∗)p(k∗)p(τ ∗|k∗)
p(y|τ, k)p(k)p(τ |k) } (4.28)
where
(τ t, kt) =
 (τ
∗, k∗) with probability r
(τ t−1, kt−1) otherwise.
(4.29)
Bayes Factor
The Bayes Factor, the ratio of the posterior and prior odds of a change point for each data
point, say z, is a useful way of indicating possible change points. We test the hypothesis of each
point being a change point against the null, which is not being a change point. Thresholding
(using typically a value of 10 or larger) the Bayes Factor (BF) of all data points will leave us
with the most likely positions of change points. The marginal prior probability is the same for
all possible change point locations and calculated using:
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p(z ∈ τ (k)) =
n∑
i=0
(
n!
i!(n− i)!)
−1(
(n− 1)!
(i− 1)!(n− 1− (i− 1))!)
p(i, q)∫ n
0
p(x, q)dx
(4.30)
=
q
n
∫ n
0
p(x, q)dx
n∑
i=0
i(1− q)i
where p(k, q) is the geometric prior density function on k, with parameter q. Using the following
relations:
prior odds =
p(z ∈ τ (k))
1− p(z ∈ τ (k)) (4.31)
posterior odds =
p(z ∈ τ (k) | y)
1− p(z ∈ τ (k) | y) (4.32)
where the marginal posterior probability of a point being a change point is computed from the
Metropolis Hastings sampling output, the Bayes Factor can be calculated for each data point.
4.2.2 Testing and Convergence
A test dataset was constructed by generating data from Normal distributions with different
parameters for five different segments. Running 10000 iterations (5000 burn-in) of the BPM
MCMC algorithm and sampling from the posterior distributions of µ and σ every 10th iteration
correctly identifies the four change points as well as the mean of each segment as illustrated by
Figure 4.4.
Convergence of the algorithm was investigated by varying the MCMC and prior parameters as
well as the information contained in the data and was found to be robust to all these factors.
Figures 4.5, 4.6 and 4.7 show convergence of the change points for three different test data
sets: a noisy signal, a signal with fewer data-points and a noisy signal with few data-points
(generated similarly to as described above). The third scenario required slightly more iterations
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Figure 4.4: Plot of test data (red), posterior mean of distribution within each partition (blue),
marginal posterior probability of each data point being a change point (green line) and those
points with a Bayes Factor >10are represented by dots at the top of the diagram.
for stability but all three cases converged relatively quickly to the correct answer. Sensitivity
of convergence to prior parameters was minimal on the test data and is explored further in the
next section using a ‘real’ signal.
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Figure 4.5: Figure shows the signal data modelled (blue scatter plot), the marginal posterior
probability of each data-point being a change point (red line plot) correctly indicating the
change points, trace plot of K over the run (blue line plot) and the posterior distribution of K
(blue histogram). The run was 6,000 iterations long including 5,000 burn-in. Prior mean on θ
was 20 and initial value of K was set to 20. Prior parameters p and q were set to 0.5 and 20
respectively and prior parameters d and s were set to 50 and 20 respectively. Despite the data
being noisy, the model converges quickly to the correct answer.
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Figure 4.6: Figure shows the signal data modelled (blue scatter plot), the marginal posterior
probability of each data-point being a change point (red line plot) correctly indicating the
change points, trace plot of K over the run (blue line plot) and the posterior distribution of K
(blue histogram). The run was 6,000 iterations long including 5,000 burn-in. Prior mean on
θ was 20 and initial value of K was set to 20. Prior parameters p and q were set to 0.5 and
20 respectively and prior parameters d and s were set to 50 and 20 respectively. Despite there
being relatively few data-points, the model again converges quickly to the correct answer.
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Figure 4.7: Figure shows the signal data modelled (blue scatter plot), the marginal posterior
probability of each data-point being a change point (red line plot) correctly indicating the
change points, trace plot of K over the run (blue line plot) and the posterior distribution of K
(blue histogram). The run was 10,000 iterations long including 5,000 burn-in. Prior mean on
θ was 20 and initial value of K was set to 20. Prior parameters p and q were set to 0.5 and 20
respectively and prior parameters d and s were set to 50 and 20 respectively. Given there was
considerable noise and few data-points, the model took slightly longer to converge but still did
so relatively quickly and to the correct answer.
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4.2.3 Sensitivity Analysis
Varying the parameters for the BPM gives us some control over the sensitivity of the peak
detection. p is related to the variance of the prior mean for each data segment. Figure 4.8(a)
shows that as we allow greater variance of the mean level, θ, we fit a larger number of change
points. q is the prior parameter on k the number of change points. The prior mean for k is
given by 1−q
q
. As expected, see Figure 4.8(b), setting a low prior mean penalises large k, so
fewer change points are detected.
Figure 4.8: Sensitivity Analysis for prior parameter (a) p and (b) q on k indicating that
increasing variance for prior on k allows greater number of change points to be fitted.
s and d are the scale and shape parameters, respectively, of the Inverse-Gamma (IG) prior
on the variance, σ. The effects of varying these parameters is more complex to gauge since
the mean and variance of the IG distribution are 1
s(d−1) and
1
s2(d−1)2(d−2) . Figure 4.9 suggest
that both parameters are approximately inversely proportional to the number of change points
detected. Increasing the value for s or d significantly means that the mean and variance both
increase, allowing large variability within each data segment and thus fitting fewer change
points.
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Figure 4.9: Sensitivity Analysis for prior parameters (a) d and (b) s indicating that increases of
d or s correspond to higher mean and variance allowing greater variability of intensity within
each partition and so fitting fewer change points.
4.2.4 Results
The BPM was run on a ‘test’ chromatogram at 264.95 m/z (0.1m/z bin), using parameters
penalising large values of k. Figure 4.10 shows that the algorithm is capable of estimating the
mean and position of peaks fairly accurately. However, the shape of the signal is not well fitted
and is an area that needs further investigation. Using a Gaussian or Exponentially Modified
Gaussian shaped design vector, x, may model the peaks more precisely. Fixing k = 2 and
requiring the centre section to be greatly different from zero provides a robust method of peak
detection, but is very computationally intense so an alternative strategy is pursued in the next
section as part of the H-MS algorithm.
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Figure 4.10: Shows the real data (red) overlaid with the posterior mean (blue) and the marginal
probability of a change point (green). Blue dots indicate points with a Bayes Factor >10. The
inset shows a close-up of a relatively low intensity peak.
4.3 H-MS: Wavelet Smoothing, Adaptive Binning and
Peak Detection
Our approach entails a combination of different methodology. H-MS consists of two main
algorithms: the first bins the data in the m/z dimension and the second performs peak detection
in the Rt dimension within each bin sequentially. This marrying of methods helps ensure that
information is not lost by splitting peaks or including unnecessary noise as is often the case
when using more primitive binning strategies. The peak detection fits chromatographic peaks
with a Gaussian or Exponentially Modified Gaussian (EMG) shape. A number of tests are
then used to determine whether a candidate peak is a ‘true’ peak. The methods are outlined in
more detail in this section, and their performance is assessed and compared to existing packages
apLC-MS and XCMS.
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4.3.1 Binning in m/z Dimension
1. Create Integrated Mass Spectrum The whole dataset for a single sample (consisting
of m/z, Rt and intensity triples) is ordered according to m/z value, and where duplicate m/z
values occur the intensity is summed. This gives us a ‘Total Mass Spectrum’ (TMS) that will
retain features of the m/z dimension of the data.
2. Smooth Spectrum
The spectrum is then transformed using the discrete wavelet transform with Daubechies 3
wavelets (commonly used to model m/z peaks [163]) as default, although other wavelets are
available in the MATLAB Wavelet Toolbox. The wavelet coefficients are then thresholded
using the universal threshold (based on the median average deviance) method with the option
to use the level dependent version [163]. H-MS has the option to perform either ‘hard’ or ‘soft’
thresholding, with the default being soft. By performing the inverse wavelet transform, we
can see the smoothed spectrum as in Figure 4.11. The wavelet transforms are calculated using
inbuilt MATLAB functions within the Wavelet Toolbox.
3. Bin Placement
Local maxima are located using a simple search. The algorithm then descends down either
side of the maximum to find the peak edges. The peak edges are defined as the position at
which the TMS signal reaches zero, or at which the signal begins to increase again. These peak
‘edges’ are then used for bin placement.
4. Filter Bins
Bins are then filtered according to a user specified ’maximum peak width’. If adjacent bins
both contain possible peaks, the position of each maximum is found. If the distance between
the peaks is less than the maximum peak-width, the bins are combined. Adjacent empty bins
are amalgamated into a single bin.
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Figure 4.11: An example Total Mass Spectrum (with zoomed inset) showing raw data in black
and the wavelet-smoothed data in red.
4.3.2 Peak Detection in Chromatographic Dimension
The Guassian (three free parameters) and Exponentially Modified Gaussian (four free param-
eters) are widely considered good models for chromatographic peak shape [164]. The Gaussian
model is described by the following equation:
f(x) = Ae−
(x−b)2
2c2 (4.33)
where b is the center of the peak, c2 is the variance and A is the amplitude. The Exponentially
Modified Gaussian (EMG) model is given by the equation:
EMG(x) =
A
τσ(2pi)1/2
∫ x
0
exp(−(x− b− x
′)2
2c2
) exp(−x
′
τ
)dx′ (4.34)
where b is the centroid maximum of the Gaussian component, c2 is the variance of the Gaussian
component, τ is the time constant of the exponential function and A is the amplitude. The
H-MS peak detection routine employs both these models in order to accurately capture differing
peak shapes.
For each bin, a chromatogram is constructed containing the data in the bin across the range
of retention times. To detect peaks within each chromatogram, the maximum within the slice
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is identified and the candidate peak area is defined within a given window of the maximum. A
number of tests are carried out within the following framework, designed to identify well-shaped
peaks:
1. Fit Gaussian Model
The Gaussian model is fitted to the candidate peak area using least squares. The peak beginning
and end are calculated as the points at which the intensity of the fit falls below either a given
proportion of the maximum intensity (default is 5 %) or a simple threshold.
2. Peak Width Check
Candidate peaks with widths (in Rt) below a specified ‘minimum peak width’ and above a
’maximum peak width’ are discarded.
3. Data-points Check
Peaks with fewer than a specified number of non-zero data-points are removed.
4. Likelihood Ratio Test
The Gaussian peak model is compared to the hypothesis of zero signal (described in further
detail in the next section).
5. Smoothing Spline Shape Test
The Gaussian peak model is compared to the fit provided by a smoothing spline in order to
reject poorly shaped peaks (described in further detail in the next section). Candidate peaks
that pass this test are considered ‘true’ peaks.
6. Fit Exponentially Modified Gaussian Model
If the candidate peak is rejected by Step 5, we consider the possibility that the peak may be
better characterized by the EMG model so Steps 2-5 are repeated using the new fit. Employing
the EMG guards against rejecting true peaks with large tails that are fitted poorly by the
standard Gaussian.
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7. Local Minima Check
If, after trying the EMG fit, the candidate peak is still rejected at Step 5, we check for the
presence of more than one peak within our candidate peak area by searching for a local minima.
The smoothing spline is re-fit but this time with less smoothing, in order to avoid local minima
arising from noisy data but retain the trough between two separate peaks. If a local minima is
found, the candidate peak area is split at the local minima resulting in a new candidate peak.
Then, the complete peak detection procedure (from Step 1) is repeated for this new candidate.
If a peak is detected, then the fitted parameters are added to the peak list and the intensity
between peak start and end is set to zero so as not to interfere with detection of further peaks
within the same slice. If no peak is detected, the candidate section of signal is discarded as noise
and set to zero. The algorithm then looks at the next maxima in the chromatogram and checks
for further peaks. The peak m/z value is calculated by taking an intensity-weighted average
of the raw data-points within the detected peak edges. The peak Rt is given by the value at
which the peak attains its maximum intensity. The peak intensity is calculated by summing
the intensity of the raw data points within the peak edges. Once there are no further maxima
in the chromatogram above the given threshold, the algorithm moves on to the chromatogram
of the next m/z bin.
Likelihood Ratio Test for Presence of Peak
The likelihood ratio for the least squares fit (alternative hypothesis) versus no peak being
present (null hypothesis) is calculated and accepted/rejected with 5% significance:
L =
p(y, µ1, σ
2
1)
p(y, µ0, σ20)
(4.35)
−2ln(L) ∼ χ2df (4.36)
where y is the data, p(y, µi, σ
2
i ) is the Normal likelihood of a particular model, µ1 is the least
squares estimate of either the Gaussian or EMG model, σ21 is the variance of the residuals of this
estimate, µ0 is a vector of zeros and σ
2
0 is the variance of the residuals from the null hypothesis.
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−2ln(L) then has a χ2 distribution with 3 (when using the Gaussian fit) or 4 (when using the
EMG fit) degrees of freedom. The degrees of freedom, df , is calculated as difference between
the number of free parameters of the alternative model and that of the null which has one free
parameter.
Smoothing Spline Shape Test
Here we use an inbuilt MATLAB smoothing spline function to model the data as the null hy-
pothesis, with our Gaussian or EMG fit as the alternative. The Bayesian Information Criterion
(see Section 3.1.2 for more details on this method of model selection) is then used to choose
between the two models since it will penalise the large number of parameters of the smoothing
spline (calculated by a MATLAB fitting routine). It is hoped that for poorly shaped candidate
peaks the spline fit will be preferred, despite the number of parameters, so the peak is rejected.
Figure 4.12: Candidate peaks accepted by smoothing spline shape test using (a) Gaussian
model and (b) Exponentially Modified Gaussian model. Blue circles indicate raw data points,
red line indicates Gaussian fit, black line indicates EMG fit and green line indicates smoothing
spline fit.
Figure 4.12 shows (a) an example of a peak detected using the Gaussian model and (b) an
example of a peak detected using the EMG model after being rejected using the Gaussian,
reinforcing the benefits of employing both models.
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4.3.3 Results and Discussion
We use a Synthetic Human Urine Sample, a Standard Dilution Series (SDS) of human urine
metabolites and simulated ‘noise’ datasets to explore the binning and peak detection capa-
bilities of H-MS. Given the variability of LC-MS datasets it was important to use multiple
sets for evaluating robustness and also the data-set selection gives scope to evaluate different
characteristics of the algorithms.
The Synthetic Human Urine Sample contains 83 different metabolites and the resulting largely
unpredictable interactions and noise should provide a good simulation of the complexities of
data arising from a real organic biofluid whilst allowing us to have prior knowledge of the
sample composition to aid peak searching and identification. Whilst using a real urine sample
where the composition is known would be the gold standard this is obviously impossible so
analysis of a realistic synthetic sample will allow evaluation of the algorithms in as close to a
‘real-life’ setting as possible where data is noisy and complex, whilst knowing the approximate
‘true answer’.
The Standard Dilution Series is a less complex mixture (14 metabolites) and as such we would
expect to see a simpler dataset set where peak detection and quantification would perhaps be
easier than for the synthetic urine sample certainly for high concentrations. The dilution series
of each metabolite should exhibit a linear trend in terms of concentration levels so examining
the peak sizes captured by the algorithms should give us a good indication of how well the
peaks are characterised. Deviations from linearity may highlight peaks that are either poorly
characterised (i.e. peaks are split or multiple peaks are grouped together) or peaks that do not
belong to the metabolite, i.e. false positives, that are much harder to identify in the synthetic
urine sample. This analysis should also show how well the algorithms distinguish between noise
and analyte peaks at lower concentrations.
We compare H-MS to the adaptive binning and peak detection algorithm apLC-MS [66] and
both the centWave and matchedFilter peak detection routines of the commonly-used package
XCMS [130, 46]. XCMS was chosen given its prominent use across the field of metabolomics
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([46] has 634 citations) and the fact that it offers two different methods for peak detection,
one of which utilises wavelet analysis in an alternative way to H-MS. apLCMS was selected for
its claim to effectively perform adaptive binning comparative to that of H-MS. As shown in
Section 4.1.2 there are a multitude of algorithms that could be compared, but for the purposes
of this section those selected give a good balance of a more traditional filtering method in
XCMS’ matched filter, a robust and highly regarded ‘gold standard’ in XCMS’ centWave and
a perhaps more innovative and unconventional method in apLCMS.
As previously mentioned, centWave uses the Continuous Wavelet Transform (CWT) to locate
chromatographic peaks on different scales and identify prominent features, whereas matchedFil-
ter uses a Mexican Hat-shaped filter to detect peaks across the Rt dimension within fixed-width
m/z slices of the data.
apLC-MS performs adaptive binning by searching for m/z tolerance level using a mixture model
and then grouping m/z values based on the tolerance level. The mixture model is based on the
assumption that the consecutive differences between values of an ordered list of the detected
m/z for a sample consist of differences within the same peak (caused by small measurement
variations) and differences between peaks and noise data-points. The differences between peaks
or noise data-points are approximated by the spacings between a sample drawn from a Uniform
distribution which can be modelled using an exponential distribution, whilst the differences of
m/z values within a single peak are modelled using an unspecified function with a maximum
value that is very small. The m/z tolerance level is then based on the estimated parameters
of the mixture model. The grouped data points are then refined using non-parametric density
estimation in both m/z dimension and elution time dimension, with groups split at valley
positions if multiple models are identified. A run filter is also applied, requiring a peak to have
a minimum length in the retention time dimension, as well as being detected among at least the
specified proportion of the time points within the time period. After this procedure, features
are fitted with a kernel smoother to determine the peak parameters, using an Expectation
Maximisation algorithm with pseudo likelihood for features with multiple peaks.
Similarly to XCMS, apLC-MS also incorporates a Retention Time alignment algorithm but as
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mentioned previously, exploring these techniques is beyond the scope of this thesis and this
pre-processing step will be ignored in order to perform a fairer comparison and evaluation of
the algorithms peak detection capabilities.
Data
Two experimental data-sets were used to evaluate the algorithms.
Synthetic Urine Sample
Preparation
Eighty-three of the most abundant endogenous mammalian metabolites, ranging in molecular
weight from 30-625 Da, were weighed into a 1-L bottle and then dissolved in 1L of HPLC-
grade water (Sigma-Aldrich, St. Louis, MO). Any remaining solids were removed by vacuum
filtration. Approximate final metabolite concentrations were targeted to fall between 1mM and
20mM, with sodium azide added at 0.05% v/v as a preservative. The normally high levels of
inorganic salts found in urine were not added, in order to eliminate the effect of salt suppression
in the various sample introduction interfaces. The stock solution was stored at -80◦C.
Instrumentation
Synthetic urine samples (5µL) were injected onto a 2.1mm × 100mm (1.7µm) HSS T3 Acquity
column (Waters Corporation, Milford, CT) and eluted using a 18-min gradient of 100% A
(water, 0.1% formic acid) to 100% B (acetonitrile, 0.1% formic acid). The flow rate was
500µL/min, the column temperature was 40◦C, and the sample temperature was 4◦C. Samples
were analysed using a UPLC system (UPLC Acquity, Waters Ltd. Elstree, U.K.) coupled online
to a Q-TOF Premier mass spectrometer (Waters MS Technologies, Ltd., Manchester, U.K.) in
positive- and negative-ion electrospray mode with a scan range of m/z 50-1000 and a scan time
of 0.08s. Three technical replicates were run. To obtain data that were as raw as possible, the
spectrometer was run in continuum mode and the detector saturation correction was switched
off. A feature of the Q-TOF Premier is that it employs a ‘DRE lens’, which is a mechanism
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for defocusing the ion beam to minimize detector saturation. This defocusing mechanism was
also switched off.
Tables 4.3.3 and 4.3.3 list the metabolites included along with their approximate concentration
and indicate whether they were manually identified in the LC-MS (positive and negative runs)
by the group who ran the experiments and also if they were detected automatically by the
algorithms evaluated.
Standard Dilution Series
Preparation
A total of 14 metabolites commonly observed in human urine were chosen as standard com-
pounds and obtained in stable isotope (2H or 13C) labelled form. All samples were prepared in a
single batch at Imperial College London. All reagents including LC-MS grade water, acetronile
with pre-added 0.1% formic acid, and standard compounds were obtained from Sigma Aldrich
(Gillingham, UK). Columns and maximum recovery vials were donated by Waters Corporation
(Milford,US). Stock mixtures of the standards (1mg/mL) were prepared and diluted to a work-
ing concentration of approximately 10µg/mL per standard. These stock solutions were subject
to four two-fold dilutions resulting in dilutions of 1, 1/2, 1/4, 1/8 and 1/16.
Instrumentation
Synthetic urine samples were analysed using a UPLC system (UPLC Acquity, Waters Ltd.
Elstree, UK) coupled online to a Q-TOF Premier mass spectrometer (Waters MS Technologies,
Ltd., Manchester, U.K.) in positive electrospray (ESI) mode with a scan range of 50-1000 m/z.
Capillary voltage was 2.4Kv, sample cone was 35V, desolvation temperature 350◦C, source
temperature 120◦C, and desolvation gas flow 900 L/hr. The Q-TOF Premier was operated
in V optics mode, with a data acquisition rate of 0.1s and a 0.01s inter-scan delay. Leucine
enkephalin (m/z 556.2771) was used as the lockmass; a solution of 200pg/µl (50:50 ACN:H2O)
was infused into the instrument at 3µl/min via an auxillary sprayer. Data were collected in
centroid mode with a scan range of 50-1000 m/z, with lockmass scans collected every 15s and
averaged over 3 scans to perform mass correction.
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Name Concentration Manually Automatically
(mM) Identified Detected
1-methylnicotinamide 1.7
3-(3-hydroxyphenyl)propionic acid 9.21
3-hydroxycinnamic acid 1.18 X X
3-methyladipic acid 23.73
3-nitro tyrosine 0.13 X
4-Aminobutanoic acid 10.09
4-aminohippuric acid 11.07 X X
4-hydroxyproline 1.14
4-methyl-2oxopentanoic acid 9.68
5-hydroxyindole acetic acid 1.57
acetamide 4.42 Outside scan range
adenosine triphosphate 0.78 X
adipic acid 11.63 X
alanine 1.83 X
allantoin 0.99
arabinose 0.74
ascorbic acid 9.48 X
betaine 3.28 X
chenodeoxycholic acid 7.82 X X
cholesteryl palmitate 0.88
choline 2.98 X
cis-aconitic acid 1.67
citric acid 10.05
creatine 1.22 X X
creatinine 1.49 X
cyclopropanedicarboxylic acid 2.21 X
D-arginine 0.72
D-asparagine 0.72
D-Aspartic acid 10.14
D-Lactic acid 5.55 X
D-lysine 2.22
D-malic acid 13.72 X
D-ornithine 0.82
D-Proline 1.01 X
D-tyrosine 1.17
ethanolamine phosphate 0.86
folic acid 7.07
fumaric acid 18.95 X
glucuronic acid 7.73
glutaric acid 10.37
glycerol 1.16 X
glycine 4.36 Outside scan range
glycolic acid 12.75 Outside scan range
hippuric acid 15.07
Table 4.2: Chemical composition of synthetic urine sample and approximate concentration of
analytes. Metabolites manually identified in LC-MS runs and those automatically detected by
at least one algorithm indicated by ‘X’.
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Name Concentration Manually Automatically
(mM) Identified Detected
homoserine 0.93 X
hypoxanthine 0.9
indoxyl sulfate 0.06 X
isobutyric acid 5.68 X
isocitric acid 14.6 X X
L-carnitine 0.9 X
L-citrulline 0.78 X X
L-Serine 1.25
L-Threonine 3.88 X
L-tryptophan 1.13 X X
mannitol 1.22
methyl succinic acid 16.35
methylamine 6.49 Outside scan range
methylmalonic acid 1.02 X
myo-inositol 1.4
N,N-dimethylbenzamide 1.31
N-acetyl-L-glutamic acid 9.52
nicotinic acid 11.7
N-Methylglycine 1.21 X
N-methyl-L-histidine 0.14
oxalacetic acid 11.74
oxoglutaric acid 9.16
phosphoenolpyruvic acid 0.07
pimelic acid 10.11 X X
propanoic acid 12.79 Outside scan range
pyruvic acid 5.68 X
riboflavin 1.05 X X
salicylic Acid 11.8
sebacic acid 10.73
suberic acid 1.95 X X
succinic acid 5.62 X
thymine 1.09 X
trimethylamine N-oxide 1.38 Outside scan range
uracil 1.12
uric acid 1.04 X X
uridine 1.4
urocanic acid 11.95
xanthine 1.09 X X
xylose 1.06
Table 4.3: continued: Chemical composition of synthetic urine sample and approximate con-
centration of analytes. Metabolites manually identified in LC-MS runs and those automatically
detected by at least one algorithm indicated by ‘X’.
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Table 4.3.3 lists the metabolites included, indicating whether they were detected by the algo-
rithms evaluated and if so, in what chemical form.
Name Detected Form(s) detected
acetylcarnitine-d3 X M, M+H, M+Na, 2M+H, 2M+Na
adipic acid-d8 X M+H
dimethylglycine-d6 X M+Na
DL-leucine-d3 X M+H, M+CO2
DL-methionine-13C X M+H, M+Na
DL-phenylalanine-13C X M+H
dopamine-d4 X M, M+H
glutaric acid-d4
heptanedioic-d4 X M+H
hippuric acid-d2 X M+H, 2M+H, 2M+Na
L-DOPA-ring-d3 X M, M+H, M+Na, 2M+H, 2M+Na
nicotinamide-d4 X M, M+Na
succinic acid-d4 X M+Na
tryptamine-d4 X M, M, M+H
Table 4.4: Chemical composition of standards dilution series batch. ‘X’ indicates detected in
any form (including dimers and adducts) in any replicate by any of the algorithms, with the
detected forms also listed.
Estimating the False Positive Rate
The null hypothesis that the sample contains no peaks was tested for the H-MS, centWave,
matchedFilter and apLC-MS. All the null hypothesis testing was repeated for a variety of
parameters for each method.
centWave has four main parameters: peak-width range (default is 20-50s), signal-to-noise
threshold (default is 10), ppm - maximum m/z deviation allowed between consecutive scans
when identifying initial ‘regions of interest’ (default is 25ppm), and the pre-filter settings (k,I)
where mass traces are only retained if they contain at least ‘k’ peaks with intensity greater
than ‘I’ (default is k = 3, I = 100). The peakwidth was varied using ranges of (2,20), (2,50)
and (20,50). The signal-to-noise thresholds used were 5,10 and 20. The ppm setting was varied
as 10,25 and 50. The prefilter settings used were (3,50), (3,100) and (5,100).
For matchedFilter, the main parameters are the ‘full width at half maximum’ of the matched
filtration Gaussian model peak (default is 30), maximum number of peaks per Extracted Ion
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Chromatogram (EIC) (default is 5) and signal-to-noise threshold (default is 10). The full width
at half maximum values used were 15,30 and 60. The maximum peaks per EIC were set at 3,
5 and 8. The signal-to-noise threshold was varied using values 5, 10 and 20.
When running apLC-MS binning, the relevant parameters are the run filter parameters, i.e
the minimum proportion of presence in the time period for a series of signals grouped by m/z
to be considered a peak (default is 0.5) and the minimum length of elution time for a series
of grouped signals to be considered a peak (default is 12), and the m/z tolerance level for the
grouping of data points expressed as a fraction of the m/z value (default is 1e-5). The minimum
proportion of presence was set at 0.3, 0.5 and 0.8. The minimum elution times used were 2, 5
and 12. The m/z tolerance values were 5e-6, 1e-5 and 5e-5.
When running H-MS, three different peakwidth ranges were used: 2-20, 2-50 and 20-50 seconds.
Maximum peakwidths in the m/z dimension were given by 0.001, 0.0025 and 0.005 Daltons.
The intensity was hard thresholded using thresholds of 50 and 100 counts.
Noisy data was simulated using a 2D Poisson point process (10 replicates with 5 different rates:
0.05, 0.01, 0.005, 0.001 and one estimated from noisy regions of the data equal to 0.0025) since
this is the distribution commonly assumed for LC-MS noise [165]. XCMS (both matchedFilter
and centWave) and H-MS correctly identified no peaks present. However, apLC-MS detected
some peaks for small values of the parameter defining the minimum elution time for a group of
data-points to be considered a peak, shown in Table 4.5.
Poisson min,run min,pres tol Mean no. Standard
Process Rate of Peaks Deviation
Data Estimate 2 0.3 1E-5 18.3 59.8
0.05 2 0.3 1E-5 0.4 0.8
0.01 2 0.3 1E-5 115.4 62.7
0.005 2 0.3 1E-5 46.6 72
0.001 2 0.3 1E-5 5.8 21.5
Table 4.5: Mean and variance of number of peaks detected by apLC-MS over 10 replicates
of noise datasets simulated using five different Poisson process rates, for a range of values
for parameters min.run (minimum length of elution time for a series of grouped signals to be
considered a peak), min.pres (minimum proportion of presence in the time period for a series of
signals grouped by m/z to be considered a peak) and tol (m/z tolerance level for the grouping
of data points expressed as a fraction of the m/z value).
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In addition, 10 ‘shuﬄed’ data sets were tested on all four methods. The shuﬄed data consisted
of the synthetic urine sample, with both intensity and m/z values randomly permuted for
fixed retention times in order to disrupt peak shape but retain data-points with a range of
intensities. Again, centWave and H-MS correctly deduced there were no true peaks present,
whilst matchedFilter and apLC-MS detected a number of peaks depending on the parameters
used, shown in Tables 4.6 and 4.7.
fwhm max snthresh Mean No. of Peaks Standard
Deviation
30 5 10 6245.7 65.8
15 5 10 10436.7 82
60 5 10 3862.1 75.8
30 3 10 6222.8 66.9
30 8 10 6246.7 66.8
30 5 5 11759.5 86.84
30 5 20 2992.4 24.6
Table 4.6: Mean and variance of number of peaks detected by matchedFilter over 10 ‘shuﬄed’
datasets for a range of values for parameters fwhm (full width at half maximum of Rt peak
model), max (maximum number of peaks per Extracted Ion Chromatogram) and snthresh
(signal-to-noise threshold).
min.run min.pres tol Mean no. of Peaks Variance
12 0.5 1E-5 243.2 16.2
5 0.5 1E-5 3144.7 93.4
20 0.5 1E-5 87 9.9
12 0.3 1E-5 5436.2 95.8
12 0.8 1E-5 21.6 4.9
12 0.5 5E-6 40.8 4.6
12 0.5 5E-5 24814.9 177.8
2 0.3 1E-5 100369.8 1243763582
Table 4.7: Mean and variance of no. of peaks detected by apLC-MS over 10 ‘shuﬄed’ datasets
for a range of parameters: min.run (min. length of Rt for a series of grouped signals to be
considered a peak), min.pres (min. proportion of presence in the time period for a series of
signals grouped by m/z to be considered a peak) and tol (m/z tolerance for the grouping of
data points expressed as a fraction of the m/z value).
Comparison using Synthetic Urine Sample
In this section, we compare the results of the H-MS binning strategy for a synthetic urine
sample, with those of apLC-MS since it also uses an adaptive method. apLC-MS bin positions
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were located by using the proc.cdf() function which performs the m/z threshold grouping and
applies the run filter. Bin positions were then determined by finding the m/z values at the
which the feature group begins/ends.
Figures 4.13 and 4.14 show two examples of H-MS outperforming apLC-MS. Here, apLC-MS
has split the Hydroxycinnamic Acid peak down the middle and the Creatine peak into several,
whilst H-MS preserves the entirety of the peak profiles. For the rest of the identified peaks while
H-MS binning offers precision for the majority and does not split them in the way apLC-MS is
shown to, apLC-MS places very large bins that are likely to contain much noise. Further figures
have not been included since the bins are too wide for illustration to be informative. Whilst
XCMS’ matched filter does not split peaks in the same way as apLC-MS, it too provides peak
parameters that are too broad to be visually compared with those of centWave and H-MS.
Figure 4.13: A 3-Hydroxycinnamic Acid peak intensity plot (a) of the raw data, with the colour
scale indicating intensity and bin edge locations shown for H-MS (red lines) and apLC-MS (cyan
lines). Also plotted are chromatograms of the H-MS bin (b) and the two apLC-MS bins (c, d).
In order to evaluate peak detection capabilities, we looked at a number of compounds present
in the synthetic urine sample and attempted to cross match them with the peaks detected by
each algorithm. Peak identification was performed by allowing a 10ppm × 20 second window
about the expected location of the metabolites. centWave was able to identify 17 different
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Figure 4.14: A Creatine peak intensity plot (a) of the raw data, with the colour scale indicating
intensity and bin edge locations shown for H-MS (red lines) and apLC-MS (cyan lines). Also
plotted are chromatograms of the H-MS bin (g) and the five apLC-MS bins (b-f).
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features relating to 12 of the metabolites. After varying parameters to get the best results
for each algorithm: H-MS and apLC-MS also correctly identified all of these features whilst
matchedFilter identified 14.
Since both apLC-MS and matchedFilter give relatively imprecise parameters for detected
‘peaks’ in comparison to H-MS and centWave, we focus on the latter two as the performance
is more comparable.
Figure 4.15, shows the raw data intensity plots for six metabolites: 4-Aminohippuric acid, 3-
Hydroxycinnamic acid, Pimelic acid, Xanthine, Riboflavin and Isocitric acid with the output
peak parameters for both H-MS and XCMS’ centWave. The results from both algorithms
are quite similar but H-MS often provides a more accurate description of the peaks. These
plots provide some useful illustration of typical peaks, but a more robust evaluation of peak
characterisation is described later in this chapter.
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Figure 4.15: Raw intensity plots, with colour scale indicating intensity, of 6 detected metabo-
lite peaks. Peak parameters shown for H-MS (red) and centWave (black) as boxes. (a) 4-
Aminohippuric acid gives an example of centWave excluding high intensity data-points but
H-MS captures the whole peak. For 3-Hydroxycinnamic acid in (b) we see a substantial drift in
m/z value within a peak. H-MS includes all of the peak, whilst centWave detects two separate
peaks. (c) Pimelic acid demonstrates where H-MS has defined a tighter area than centWave, in-
cluding less noise. (d) Xanthine and (e) Riboflavin shows where H-MS excludes some relatively
high intensity data-points that are captured by centWave. In (f) H-MS includes some lower
intensity datapoints surrounding the Isocitric acid peak which perhaps should not be included
as per the centWave parameters.
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Comparison using Standard Dilution Series
centWave and H-MS were run on each sample separately (no across-sample peak matching
or Retention Time alignment was performed using centWave for a fairer comparison). The
resulting peak lists were cross matched with the standard compounds and common adducts
and dimers within a 10ppm × 20 second window of the expected peak locations, as determined
by a pilot study. Table 4.8 details the average number of peaks detected by each algorithm
across the three replicates at each dilution, along with the average number of peaks matched
at expected peak locations. The fact that centWave matches more expected peaks could be
indicative of greater sensitivity than H-MS, whilst the higher ratio of peaks matched to peaks
detected at lower dilutions could suggest H-MS boasts better specificity. However, there are
likely to be many unknown peaks expressed in the data (perhaps close to the expected peak
locations) so we cannot be certain that peaks have not been mismatched.
Dilution centWave Peak centWave Total H-MS Peak H-MS Total
Level Matches Peaks Matches Peaks
1 18.7 376.0 16.3 311.0
0.5 20.7 329.0 13.7 264.0
0.25 17.7 284.0 15.0 238.7
0.125 11.3 254.3 10.7 195.3
0.0625 10.0 233.7 9.0 169.7
Table 4.8: Average total number of detected and average number of matched peaks for centWave
and H-MS algorithms for each dilution level.
Looking at the metabolites (or adducts/dimers thereof) that are detected across all five dilutions
for each set of replicates, we can plot the intensity curves for each. Given the dilution series, we
expect to find a linear relationship between dilution and intensity, ignoring possible saturation
or limit of detection effects. H-MS detects 8 additional peaks consistently across the dilution
series, whereas centWave only detects 4. Figure 4.16 shows those peaks detected for both H-MS
and centWave, whilst Figures 4.17 (a) and (b) show the peaks detected only by H-MS and only
by centWave respectively.
Most of the intensity curves can be well approximated by a linear function as expected, although
there are a few exceptions (see Tables 4.9-4.11). Those that did not exhibit a clear linear
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Figure 4.16: Intensity curves for all peaks detected by both a) H-MS and b) centWave across the
entire dilution series. The legend gives the molecule names, with the number in front indicating
the replicate sample (1, 2 or 3). Strong linear trends give confidence that metabolites have been
accurately identified and matched.
Figure 4.17: Intensity curves for all peaks detected by either H-MS, a) with closeup b), and
centWave only, c) with closeup d), across the entire dilution series. The legend gives the
molecule names, with the number in front indicating the replicate sample (1, 2 or 3). Lack of
linear trend may be due to ion suppression or saturation effects.
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relationship were inspected by eye to avoid falsely matched peaks. For example, Figure 4.18
shows three intensity plots for peaks that are detected and matched with a particular compound,
but do not fit the linear function well. One possible explanation for the poor fit is that although
the algorithm detects a peak, it may not be well quantified, e.g. the acetylcarnitine-d3+Na
adduct is poorly characterised by centWave in Figure 4.18 b). These exceptions may also be
due to unforeseen ion suppression effects or saturation in different samples.
Figure 4.18: Raw intensity plots, with the colour scale indicating intensity (ion count) at a
particular data point, of (a) Hippuric acid-d2+H peak detected by both H-MS and centWave
in replicate 1, (b) acetylcarnitine-d3+Na peak detected by centWave in replicate 1 and (c)
2-acetylcarnitine-d3+H peak detected by H-MS in replicate 2. Peak output parameters shown
for H-MS (red) and centWave (black) as boxes.
Rep Peak H-MS centWave
1 Hippuric Acid-d2 @ [M+H]+ 0.685 0.330
2 DL-Leucine-d3 @ [M+H]+ 0.981 0.980
2 DL-Methionine-13C @ [M+H]+ 0.925 0.911
2 Hippuric Acid-d2 @ [M+H]+ 0.967 0.976
2 L-DOPA-Ring-d3 @ [M+H]+ 0.971 0.892
2 Nicotinamide-d4 @ [M+H]+ 0.976 0.962
3 Acetylcarnitine-d3 @ [M+H]+ 0.994 0.997
3 DL-Leucine-d3 @ [M+H]+ 0.993 0.990
3 DL-Methionine-13C @ [M+H]+ 0.925 0.920
3 DL-Phenylalanine-13C @ [M+H]+ 0.995 0.989
3 Hippuric Acid-d2 @ [M+H]+ 0.911 0.930
3 L-DOPA-Ring-d3 @ [M+H]+ 0.967 0.964
3 Nicotinamide-d4 @ [M+H]+ 0.988 0.972
Table 4.9: R2 for linear model fitted to dilution curves of peaks detected by both H-MS and
centWave across all dilution levels.
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Rep Peak R2
1 Acetylcarnitine-d3 @ [M+H]+ 0.037
1 DL-Methionine-13C @ [M+H]+ 0.312
1 DL-Phenylalanine-13C @ [M+H]+ 0.003
1 L-DOPA-Ring-d3 @ [M+H]+ 0.004
1 Nicotinamide-d4 @ [M+H]+ 0.000
1 Tryptamine-d4 @ [M+H]+ 0.000
2 Acetylcarnitine-d3 @ [M+H]+ 0.900
2 DL-Phenylalanine-13C @ [M+H]+ 0.694
Table 4.10: R2 for linear model fitted to dilution curves of peaks detected by H-MS but not
centWave across all dilution levels.
Rep Peak R2
1 Acetylcarnitine-d3 @ [M+Na]+ 0.058
2 Acetylcarnitine-d3 @ [M+Na]+ 0.002
2 Tryptamine-d4 @ [M+H]+ 0.955
3 Acetylcarnitine-d3 @ [M+Na]+ 0.000
Table 4.11: R2 for linear model fitted to dilution curves of peaks detected by centWave but not
H-MS across all dilution levels.
True Positive Rate
Peaks detected by H-MS in the SDS samples were also used to estimate the true positive
detection rate. A random sample of 5% of all peaks detected across the fifteen samples for H-
MS and centWave were independently scrutinised by 3 LC-MS experts within Imperial College
London, UK, who gave their opinion on whether each detected peak was a true analyte peak or
not, without knowledge of which algorithm had detected the peak. This gave us an estimated
true positive discovery rate of 70.1% for both H-MS and centWave with standard deviations of
43% and 40% respectively. This survey again indicates that H-MS performs very similarly to
centWave.
4.3.4 Conclusion
H-MS is a strategy that competes well alongside XCMS’ centWave, as well as outperforming
both the matchedFilter routine and the adaptive binning capabilities of apLC-MS. The m/z
binning routine provides an effective alternative to fixed bin widths, whilst the Gaussian/EMG
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peak detection proves to be an efficient method with a sensitivity comparable with centWave.
Analysis of simulated ‘noise’ datasets showed apLCMS and matchedfilter to be more sensitive
to false positives than centWave and H-MS when their parameters were relaxed. In exploring
the synthetic urine it was found that apLCMS binning was error prone and both apLCMS
and matchedfilter produced very imprecise peak parameters compared to centWave and H-MS.
Some identified peaks illustrated how both centWave and H-MS sometimes did not optimally
characterise the peaks either by including too many surrounding low intensity data-points
(possible noise) or conversely did not capture some important high intensity points. This is
likely due to both algorithms utilising some prescribed LC peak shape (mexican hat, Gaussian
or EMG) which true analyte peaks will not always conform to.
The expert review of peaks detected for centWave and H-MS highlighted the similar perfor-
mance with both algorithms estimated to have a good true positive rate of 70.1%. Analysis
of the linearity of metabolite peak intensities detected across the standard dilution series also
yielded very similar results but with both algorithms detecting some extra features that the
other did not. H-MS detected several extra metabolite peaks consistently across dilutions de-
spite detecting a smaller number of peaks overall, perhaps suggesting greater sensitivity and
specificity over a range concentrations.
Evaluating and comparing performance of a peak detection algorithm effectively is difficult
since even with synthetic mixtures we cannot be certain of the ‘correct answer’ because of
the unknowns of metabolite interactions and effects. The gold standard for a peak detection
algorithm really is undefined and this is particularly evident in the variance of responses to
the expert review of detected peaks. Further rigorous testing could be performed by repeating
this comparison across multiple instrumental configurations and examining the robustness of
results in order to further illuminate strengths and weaknesses of the algorithm. For example,
H-MS and centWave employ slightly different LC peak models that may be more suited to
a particular type of LC columns or mobile phase flow method. For now, H-MS is shown to
perform as well as one of the most commonly used methods in metabolomics and in some cases
provides more accurate peak identification and description. Although it shares a similar error
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rate to centWave, H-MS seems to provide a slightly different view of the data to centWave and
the algorithm may work well as a complementary/alternative routine in XCMS.
Chapter 5
Conclusion
According to a survey conducted by the American Society for Mass Spectrometry in 2009
(which can be found at www.metabolomicssurvey.com), a large number of researchers believe
the biggest bottleneck within metabolomics is metabolite identification, followed by assigning
biological significance then data processing/reduction. Although the reproducibility and accu-
racy of analytical techniques and the statistical methods for processing and interpreting the
data have improved, the problems highlighted by the survey persist in the face of a huge diver-
sity of molecular structures and variation of abundance [166]. Searching libraries of reference
spectra to compare with experimental data is the most reliable method of metabolite identifi-
cation but is a non-trivial task [167]. Metabolite spectral databases are continually expanding
to include data for an increasing range of experimental conditions, biofluids and organisms.
Attempting to match unknown spectral peaks with reference standards can throw up hundreds
of candidate metabolites for both NMR and MS based techniques and there is a considerable
amount of research devoted to developing spectral matching algorithms and ranking the results
[167, 166, 53].
The more challenging alternative to using databases of reference spectra, is to interpret the
metabolomic data in the context of metabolite molecular structure. Combining analytical tech-
niques to give complementary information on the chemical structure of a molecule is essential
in achieving the gold standard of metabolite identification. This method relies on the accuracy
121
122 Chapter 5. Conclusion
of the statistical methods employed to extract this information from complex spectral data not
only by modelling data characteristics, but also the chemical processes occurring during data
acquisition as a result of both the technique used and the interactions between metabolites and
the contaminants introduced during sample processing.
The second major difficulty in metabolomics research, assigning biological significance, is a
problem faced further along the typical experiment pipeline. Interpreting results within the
systems biology framework can be a complex task, but once again database evolution may prove
to be the way forward. In addition to the databases solely concerned with mapping metabolic
pathways, metabolite databases such as the HMDB, increasingly provide cross-references to
related metabolites, processes and organism responses and statuses. Work on integrating ‘omics’
data right across systems biology is ongoing and will undoubtedly be invaluable in placing
metabolomics discoveries within a biologically meaningful context.
Thirdly, despite the obvious benefits, increasingly sensitive analytical techniques clearly pose
a difficult challenge to metabolomics researchers. The vast datasets produced are incredibly
difficult to explore in an intelligible way, so require pre-processing and dimension reduction. In
Chapter 4 we reviewed a a number of different techniques common to LC-MS, of which many
are applicable to other analytical platforms. This is a rich and diverse area of algorithm devel-
opment benefitting immensely from the development of signal processing techniques in other
disciplines, such as image processing. Similarly to the way in which metabolite identification
relies on accurate data pre-processing methods, the advance of pre-processing algorithms relies
on improved knowledge of biofluid composition and reliable models of interactions between the
metabolites within it.
This thesis tackled three data analysis problems involved in widening the metabolomics bottle-
neck. In Chapter 2 we addressed the need to simulate metabolic data profiles in order to test
and develop new statistical methods based on 1H-NMR metabolomic profiles. MetAssimulo
is a useful simulation tool for complex 1H-NMR mixtures that is able to construct realistic
human urine spectra with inter-metabolite correlations and peak positional variation. The user
has complete control over numerous parameters involved in the simulation process, meaning
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MetAssimulo has the capability to simulate profiles for many other biofluids and species. How-
ever, further work is needed to enable compatibility with other metabolite databases required
for addressing other organisms. Development of techniques for modelling interactions and ef-
fects observed in 1H-NMR spectra is ongoing, for example the effect of pH on peak positions
examined in Chapter 3, so there will be opportunity to incorporate more realistic effects in the
future.
Modelling phenomena affecting metabolite expression in 1H-NMR spectra is a useful endeavour,
not only for data simulators such as MetAssimulo, but also for the deconvolution of complex
spectra and metabolite identification. The ability to predict peak positional variation dependent
on the pH of a mixture would be invaluable in developing automated processing techniques.
Conversely, identifying the pH of a biofluid from the position of a known metabolite peak
or predicting the number of protonation sites of a molecule from titration curves would help
in determining the chemical structure and identity of unknown metabolites. In Chapter.3 a
Bayesian non-linear regression model was used to fit a polyprotic model and showed good
parameter estimation. Attempts were also made to identify a method for choosing the model
correctly reflecting the number of sites of the molecule. However, despite exploring several
model selection criteria as well as modifying the model itself to include possible structured
variation and borrow strength across multiple chemical shifts by employing random effects,
no consistent solution was found. The model could benefit from being programmed using a
reversible jump algorithm to perform model selection.
In Chapter 4, we turned our attention to the pre-processing of LC-MS data, in particular de-
noising and peak detection. After exploring some of the various methods employed to tackle
the challenges faced in analysing LC-MS data, a novel Bayesian Partition Model (BPM) was
developed with the aim of performing peak detection in the chromatographic domain. The
BPM was effective at modelling changes in signal level, but ultimately proved too computa-
tionally intensive to compete with existing methods. A more efficient algorithm, H-MS was
created using wavelet smoothing, adaptive binning and a combination of Gaussian and Ex-
ponentially Modified Gaussian peak detection. The resulting method was tested extensively
using a synthetic urine sample to identify known compounds, with further testing performed
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on a standard dilution series to asses its ability to detect metabolites across a range of concen-
trations. In comparison to existing methods, H-MS outperformed both the adaptive package
apLCMS and XCMS’s matchedFilter. It competed well with XCMS’s centWave method, often
more appropriately describing peaks and proving more consistent across the dilution series.
H-MS could become a useful package for those looking for an effective alternative to existing
methods. Further work on decreasing the run-time of the algorithm could increase its efficiency
and appeal to potential users. The algorithm could also be extended to perform additional
pre-processing tasks, such as Retention Time alignment and matching peaks across samples.
Algorithms such as XCMS and H-MS could also benefit from the development of true 2-
dimensional processing techniques, rather than performing peak detection on chromatograms
after m/z binning. Methods capable of exploiting the information available as peaks drift in
both dimensions is vital in avoiding the pitfalls of reducing analysis to a single dimension.
Wavelet decomposition can be extended to two dimensions and has already been applied in
analysing gas chromatogram differential mobility spectrometry signals with a similar 2-D struc-
ture to LC-MS [168] and used to de-noise LC-MS spectra in proteomics [169]. Given the level
of complexity and size of digital imaging data across scientific disciplines, methods developed
within the arena of image processing are likely to play an important role in the analysis of
2-D data for numerous areas of research. It is important for the metabolomic community to
continue to mine these valuable interdisciplinary statistical resources in striving to transform
noisy raw data into biologically meaningful information.
Metabolomics is a burgeoning field of study, with continuous technological advancement. De-
velopment of data modelling and simulation techniques incorporating evermore prior knowledge
is vital to furthering our knowledge of metabolomics, the metabolome and its relationship to
the other ‘omics’. The methods described within this thesis contribute to this development
both in 1H-NMR and LC-MS data analysis, in addition to providing further possible avenues
of useful research.
Appendices
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.1 Glossary of Abbreviations
AIC Akaike Information Criterion
apLCMS LC-MS processing software [66]
BIC Bayesian Information Criterion
DIC Deviance Information Criterion
CPO Conditional posterior ordinate
CWT Continuous wavelet transform
DWT Discrete wavelet transform
EIC Extracted Ion Chromatogram
EMG Exponentially modified gaussian model
ESI Electrospray Ionization
GC-MS Gas Chromatography Mass Spectrometry
HMDB Human Metabolome Database
H-MS LC-MS peak detection algorithm developed by the author
JAGS Just Another Gibbs Sampler
LC-MS Liquid Chromatography Mass Spectrometry
LPML Log Pseudo Marginal Likelihood
MCMC Markov Chain Monte Carlo
MSE Mean squared error
m/z Mass-to-charge ratio
NMR Nuclear Magnetic Resonance
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NSSD NMR Standard Spectra Database
PCA Principal components analysis
PLS Partial least squares analysis
Rt Retention Time
SNR Signal to noise ratio
STOCSY Statistical Total Correlation Spectroscopy
TOF Time of Flight (mass spectrometry)
XCMS LC-MS and GC-MS processing software [46]
.2 Log Marginal Likelihood Estimation Algorithm
A linear iterative algorithm for estimating the log marginal likelihood of a model from [101].
Where Lt is a sample of the log likelihoods for t = 1, .., T . Firstly, the log likelihoods are
mean-centred are exponentiated:
for t = 1 : T
ft = exp(Lt − L¯t)
end
Where L¯t is the mean of the log likelihood sample. The (centred) marginal likelihoods are then
revised:
γ1 = 1
for j = 2 : 10
Aj = 0
Bj = 0
for t = 1 : T
Aj = Aj +
ft
δγj−1+(1−δ)ft
Bj = Bj +
1
δγj−1+(1−δ)ft
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end
γj =
(1−δ)T+Aj
(1−δ)T/γj−1+Bj
end
where δ = 0.01, giving the estimate:
log(MˆL) = log(γ10) + L¯t
.3 Marginal Likelihood Derivation for Bayesian Normal-
Inverse-Gamma Models
This theorem is taken from [170] and provides a useful result for deriving the form of the
marginal likelihood for Bayesian Normal-Inverse-Gamma models, used in the development of
the Bayesian Partition Model earlier in the chapter.
Theorem
Suppose that the p-vector y and the n-vector θ are related via the conditional distribution
y | θ ∼ N(F ′θ, V ) (1)
where the (n× p) matrix F and the (p× p) positive definite symmetric matrix V are constant.
An equivalent statement is
y = F ′θ + ν (2)
where ν ∼ N(0, V ). The marginal distribution of θ is given by
θ ∼ N(a, R) (3)
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where both a and R are constant, and that θ is independent of ν. Equivalently,
θ = a + ω (4)
where ω ∼ N(0, R) independently of ν. From these distributions it is possible to construct the
joint distribution for y and the conditional for (θ | y).
Since θ = a+ω and y = F ′θ+ν = F ′a+F ′ω+ν, then the vector (y′, θ′) is a linear transformation
of (ν ′, ω′)′. By construction the latter has a multivariate normal distribution, so that y and θ
are jointly normal. Furthermore:
1. E[θ] = a and V [θ] = R
2. E[y] = E[F ′θ = ν] = F ′E[θ] + E[ν] = F ′a and
V [y] = V [F ′θ + ν] = F ′V [θ]F + V [ν] = F ′RF + V
3. C[y, θ] = C[F ′θ + ν, θ] = F ′C[θ, θ] + C[ν, θ] = F ′R
It follows that
(
y
θ
)
∼ N
[F ′a
a
]
,
 F ′RF + V F ′R
RF R

 (5)
Therefore, we have:
4. y ∼ N [F ′a, F ′RF + V ]
5. (θ | y) ∼ N(m, C)
where
m = a + Ae
C = R− AQA′
A = RFQ−1
Q = F ′RF + V
e = y − F ′a
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.4 Code
The MATLAB code for MetAssimulo,the BPM and H-MS as well as the R code for the PH
Model are included on disc.
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